Ronald N Jones

List of Publications by Year
in descending order

794	44,296	2215 99	6996 154
papers	citations	h-index	g-index

799	799	799	21319
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming Patients. Open Forum Infectious Diseases, 2020, 7, ofaa084.	0.9	8
2	Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST). Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	32
3	Activity of Plazomicin Tested against Enterobacterales Isolates Collected from U.S. Hospitals in 2016â€“2017: Effect of Different Breakpoint Criteria on Susceptibility Rates among Aminoglycosides. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	14
4	The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	307
5	Geographic and Temporal Patterns of Antimicrobial Resistance in Pseudomonas aeruginosa Over 20 Years From the SENTRY Antimicrobial Surveillance Program, 1997â€“2016. Open Forum Infectious Diseases, 2019, 6, S63-S68.	0.9	84
6	Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results From the SENTRY Antimicrobial Surveillance Program, 1997â€“2016. Open Forum Infectious Diseases, 2019, 6, S54-S62.	0.9	70
7	Antimicrobial Resistance Surveillance and New Drug Development. Open Forum Infectious Diseases, 2019, 6, S5-S13.	0.9	10
8	The Importance of Antimicrobial Resistance Monitoring Worldwide and the Origins of SENTRY Antimicrobial Surveillance Program. Open Forum Infectious Diseases, 2019, 6, S1-S4.	0.9	49
9	Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program. Open Forum Infectious Diseases, 2019, 6, S23-S33.	0.9	124
10	Application of Next-Generation Sequencing for Characterization of Surveillance and Clinical Trial Isolates: Analysis of the Distribution of Î²-lactamase Resistance Genes and Lineage Background in the United States. Open Forum Infectious Diseases, 2019, 6, S69-S78.	0.9	45
11	Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program. Open Forum Infectious Diseases, 2019, 6, S47-S53.	0.9	132
12	Antimicrobial Susceptibility of Streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific Region: Results From 20 Years of the SENTRY Antimicrobial Surveillance Program (1997â€“2016). Open Forum Infectious Diseases, 2019, 6, S14-S23.	0.9	56
13	Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997â€“2016. Open Forum Infectious Diseases, 2019, 6, S79-S94.	0.9	456
14	Antimicrobial Susceptibility of Acinetobacter calcoaceticusâ€“Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997â€“2016). Open Forum Infectious Diseases, 2019, 6, S34-S46.	0.9	136
15	Antimicrobial activity of ceftazidimeâ€“avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013â€“2014). Diagnostic Microbiology and Infectious Disease, 2017, 87, 261-265.	1.8	6
16	Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	24
17	WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	63
18	Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals. Pediatric Infectious Disease Journal, 2017, 36, 486-491.	2.0	19

#	Article	IF	Citations
19	WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant Î²-lactamases. Journal of Antimicrobial Chemotherapy, 2017, 72, 1696-1703.	3.0	81
20	Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations. Diagnostic Microbiology and Infectious Disease, 2017, 88, 184-187.	1.8	13
21	Ceftaroline Activity Against Multidrug-Resistant Streptococcus pneumoniae from U.S. Medical Centers (2014) and Molecular Characterization of a Single Ceftaroline Nonsusceptible Isolate. Microbial Drug Resistance, 2017, 23, 571-579.	2.0	11
22	Prevalence of macrolideâ€“lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents. Journal of Global Antimicrobial Resistance, 2017, 8, 28-32.	2.2	8
23	The application of in vitro surveillance data for antibacterial dose selection. Current Opinion in Pharmacology, 2017, 36, 130-138.	3.5	4
24	Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014. Antimicrobial Agents and Chemotherapy, 2016, 60, 5393-5399.	3.2	32
25	Surveillance for linezolid resistance via the Zyvox^{Â®}Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates. Journal of Antimicrobial Chemotherapy, 2016, 71, 1860-1865.	3.0	63
26	In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011â€“2013). International Journal of Antimicrobial Agents, 2016, 47, 495-499.	2.5	16
27	Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011â€“2014). International Journal of Antimicrobial Agents, 2016, 48, 144-150.	2.5	52
28	Changes in the Frequencies of Î²-Lactamase Genes among Enterobacteriaceae Isolates in U.S. Hospitals, 2012 to 2014: Activity of Ceftazidime-Avibactam Tested against Î²-Lactamase-Producing Isolates. Antimicrobial Agents and Chemotherapy, 2016, 60, 4770-4777.	3.2	53
29	Ceftaroline activity tested against viridans group streptococci from US hospitals. Diagnostic Microbiology and Infectious Disease, 2016, 84, 232-235.	1.8	6
30	Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia , and Burkholderia cepacia species complex isolates from a global surveillance program (2013). Diagnostic Microbiology and Infectious Disease, 2016, 85, 352-355.	1.8	28
31	Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014). Antimicrobial Agents and Chemotherapy, 2016, 60, 3419-3425.	3.2	4
32	Results from the Solithromycin International Surveillance Program (2014). Antimicrobial Agents and Chemotherapy, 2016, 60, 3662-3668.	3.2	28
33	Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012â€“2014. Surgical Infections, 2016, 17, 473-478.	1.4	13
34	Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014. Antimicrobial Agents and Chemotherapy, 2016, 60, 4355-4360.	3.2	26
35	Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013â€“2014). Diagnostic Microbiology and Infectious Disease, 2016, 86, 300-302.	1.8	6
36	Effect of the Î²-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2016, 60, 5454-5458.	3.2	121

#	Article	IF	Citations
37	In vitro spectrum of pexiganan activity; bactericidal action and resistance selection tested against pathogens with elevated MIC values to topical agents. Diagnostic Microbiology and Infectious Disease, 2016, 86, 66-69.	1.8	11
38	Activity of Fusidic Acid Tested against Staphylococci Isolated from Patients in U.S. Medical Centers in 2014. Antimicrobial Agents and Chemotherapy, 2016, 60, 3827-3831.	3.2	22
39	High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-Î²-lactamase Production inEnterobacteriaceaeBloodstream Infections at a Major Cancer Center: Table 1.. Clinical Infectious Diseases, 2016, 63, 954-958.	5.8	55
40	Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, againstCandidaandAspergillusspp., including echinocandin- and azole-resistant isolates. Journal of Antimicrobial Chemotherapy, 2016, 71, 2868-2873.	3.0	85
41	Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline Surveillance Program (2012â€“2014). Diagnostic Microbiology and Infectious Disease, 2016, 86, 76-79.	1.8	32
42	In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014. Antimicrobial Agents and Chemotherapy, 2016, 60, 2537-2541.	3.2	30
43	Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011â€“2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin. Journal of Chemotherapy, 2016, 28, 83-88.	1.5	9
44	Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model. Antimicrobial Agents and Chemotherapy, 2016, 60, 2075-2080.	3.2	40
45	In vitroantimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. Journal of Antimicrobial Chemotherapy, 2016, 71, 670-677.	3.0	150
46	Reproducibility of dalbavancin MIC test results and an updated surrogate accuracy analysis of vancomycin MIC values to infer dalbavancin susceptibility (2014). Diagnostic Microbiology and Infectious Disease, 2016, 86, 249-251.	1.8	4
47	Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers. Surgical Infections, 2016, 17, 443-447.	1.4	12
48	Oritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results. Antimicrobial Agents and Chemotherapy, 2016, 60, 3817-3820.	3.2	2
49	Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014). Antimicrobial Agents and Chemotherapy, 2016, 60, 2273-2280.	3.2	80
50	Î²-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates. Antimicrobial Agents and Chemotherapy, 2016, 60, 1328-1335.	3.2	24
51	In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients. International Journal of Antimicrobial Agents, 2016, 47, 235-242.	2.5	30
52	Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility. Antimicrobial Agents and Chemotherapy, 2016, 60, 3174-3177.	3.2	14
53	Klebsiella pneumoniae Isolate from a New York City Hospital Belonging to Sequence Type 258 and CarryingblaKPC-2andblaVIM-4. Antimicrobial Agents and Chemotherapy, 2016, 60, 1924-1927.	3.2	15
54	Mechanisms of Resistance, Clonal Expansion, and Increasing Prevalence of Acinetobacter baumannii Strains Displaying Elevated Tigecycline MIC Values in Latin America. Microbial Drug Resistance, 2016, 22, 253-258.	2.0	23

#	Article	IF	Citations
55	Performance of BD Max StaphSR for Screening of Methicillin-Resistant Staphylococcus aureus Isolates among a Contemporary and Diverse Collection from 146 Institutions Located in Nine U.S. Census Regions: Prevalence of mecA Dropout Mutants. Journal of Clinical Microbiology, 2016, 54, 204-207.	3.9	15
56	Genotypic Characterization of Methicillin-ResistantStaphylococcus aureusRecovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole. Microbial Drug Resistance, 2016, 22, 53-58.	2.0	5
57	Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011â€“13): Table 1.. Journal of Antimicrobial Chemotherapy, 2016, 71, 276-278.	3.0	20
58	Ceftaroline Activity against Bacterial Pathogens Frequently Isolated in U.S. Medical Centers: Results from Five Years of the AWARE Surveillance Program. Antimicrobial Agents and Chemotherapy, 2015, 59, 2458-2461.	3.2	27
59	Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013. Antimicrobial Agents and Chemotherapy, 2015, 59, 3656-3659.	3.2	74
60	In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program. Antimicrobial Agents and Chemotherapy, 2015, 59, 5007-5009.	3.2	44
61	Validation of Sensititre Dry-Form Broth Microdilution Panels for Susceptibility Testing of Ceftazidime-Avibactam, a Broad-Spectrum-Î²-Lactamase Inhibitor Combination. Antimicrobial Agents and Chemotherapy, 2015, 59, 5036-5039.	3.2	7
62	In Vitro Spectrum of Pexiganan Activity When Tested against Pathogens from Diabetic Foot Infections and with Selected Resistance Mechanisms. Antimicrobial Agents and Chemotherapy, 2015, 59, 1751-1754.	3.2	59
63	Activity of Debio1452, a FabI Inhibitor with Potent Activity against Staphylococcus aureus and Coagulase-Negative Staphylococcus spp., Including Multidrug-Resistant Strains. Antimicrobial Agents and Chemotherapy, 2015, 59, 2583-2587.	3.2	30
64	In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012. Mycoses, 2015, 58, 209-214.	4.0	34
65	Validation of a Commercial Dry-Form Broth Microdilution Device (Sensititre) for Testing Tedizolid, a New Oxazolidinone. Journal of Clinical Microbiology, 2015, 53, 657-659.	3.9	8
66	Detection of a New cfr -Like Gene, cfr (B), in Enterococcus faecium Isolates Recovered from Human Specimens in the United States as Part of the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy, 2015, 59, 6256-6261.	3.2	124
67	Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009â€“2013). Journal of Global Antimicrobial Resistance, 2015, 3, 161-165.	2.2	14
68	Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011â€“2014). Diagnostic Microbiology and Infectious Disease, 2015, 83, 389-394.	1.8	25
69	Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010â€“2013). Diagnostic Microbiology and Infectious Disease, 2015, 83, 183-186.	1.8	58
70	Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010â€“2012). Journal of Antibiotics, 2015, 68, 556-561.	2.0	50
71	Accuracy of the Thermo Fisher Scientific (Sensititreâ„¢) dry-form broth microdilution MIC product when testing ceftaroline. Diagnostic Microbiology and Infectious Disease, 2015, 81, 280-282.	1.8	4
72	In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program. Diagnostic Microbiology and Infectious Disease, 2015, 81, 283-289.	1.8	25

#	Article	IF	Citations
73	Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. International Journal of Antimicrobial Agents, 2015, 46, 53-59.	2.5	75
74	Telavancin In Vitro Activity against a Collection of Methicillin-Resistant Staphylococcus aureus Isolates, Including Resistant Subsets, from the United States. Antimicrobial Agents and Chemotherapy, 2015, 59, 1811-1814.	3.2	24
75	Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011â€“2013). Journal of Global Antimicrobial Resistance, 2015, 3, 36-39.	2.2	3
76	Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method. Diagnostic Microbiology and Infectious Disease, 2015, 81, 275-279.	1.8	42
77	Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. Diagnostic Microbiology and Infectious Disease, 2015, 82, 73-77.	1.8	34
78	Arbekacin Activity against Contemporary Clinical Bacteria Isolated from Patients Hospitalized with Pneumonia. Antimicrobial Agents and Chemotherapy, 2015, 59, 3263-3270.	3.2	26
79	Update on Linezolid In Vitro Activity through the Zyvox Annual Appraisal of Potency and Spectrum Program, 2013. Antimicrobial Agents and Chemotherapy, 2015, 59, 2454-2457.	3.2	17
80	Ceftazidime-Avibactam Activity Tested against Enterobacteriaceae Isolates from U.S. Hospitals (2011 to) Tj ETQq0 0 0 rgBT /Overlock 1 2015, 59, 3509-3517.	3.2	104
81	Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide. Diagnostic Microbiology and Infectious Disease, 2015, 83, 379-381.	1.8	33
82	Microbiological Assessment of Polymyxin B Components Tested Alone and in Combination. Antimicrobial Agents and Chemotherapy, 2015, 59, 7823-7825.	3.2	8
83	Determination of Disk Diffusion and MIC Quality Control Guidelines for Solithromycin, a Novel Fluoroketolide Antibacterial, against Neisseria gonorrhoeae. Journal of Clinical Microbiology, 2015, 53, 3888-3890.	3.9	4
84	Analysis of Vancomycin Susceptibility Testing Results for Presumptive Categorization of Telavancin. Journal of Clinical Microbiology, 2015, 53, 2727-2730.	3.9	8
85	Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA. Diagnostic Microbiology and Infectious Disease, 2015, 81, 183-188.	1.8	21
86	Baseline Activity of Telavancin against Gram-Positive Clinical Isolates Responsible for Documented Infections in U.S. Hospitals (2011-2012) as Determined by the Revised Susceptibility Testing Method. Antimicrobial Agents and Chemotherapy, 2015, 59, 702-706.	3.2	21
87	Effects of Breakpoint Changes on Carbapenem Susceptibility Rates ofEnterobacteriaceae: Results from the SENTRY Antimicrobial Surveillance Program, United States, 2008 to 2012. Canadian Journal of Infectious Diseases and Medical Microbiology, 2014, 25, 285-287.	1.9	20
88	Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). Diagnostic Microbiology and Infectious Disease, 2014, 80, 233-238.	1.8	44
89	Retrospective Molecular Analysis of DIM-1 Metallo-Î²-Lactamase Discovered in Pseudomonas stutzeri from India in 2000. Antimicrobial Agents and Chemotherapy, 2014, 58, 596-598.	3.2	10
90	Oritavancin Activity against Staphylococcus aureus Causing Invasive Infections in U.S. and European Hospitals: a 5-Year International Surveillance Program. Antimicrobial Agents and Chemotherapy, 2014, 58, 2921-2924.	3.2	30

#	Article	IF	Citations
91	Post-Î²-Lactamase-Inhibitor Effect of Tazobactam in Combination with Ceftolozane on Extended-Spectrum-Î²-Lactamase-Producing Strains. Antimicrobial Agents and Chemotherapy, 2014, 58, 2434-2437.	3.2	8
92	Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value. Journal of Chemotherapy, 2014, 26, 333-338.	1.5	45
93	Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel. Journal of Chemotherapy, 2014, 26, 202-210.	1.5	12
94	Activity of Ceftaroline-Avibactam Tested Against Contemporary Enterobacteriaceae Isolates Carrying Î²-Lactamases Prevalent in the United States. Microbial Drug Resistance, 2014, 20, 436-440.	2.0	15
95	Revised Reference Broth Microdilution Method for Testing Telavancin: Effect on MIC Results and Correlation with Other Testing Methodologies. Antimicrobial Agents and Chemotherapy, 2014, 58, 5547-5551.	3.2	42
96	Quality Control MIC Ranges Used for Telavancin with Application of a Revised CLSI Reference Broth Microdilution Method. Journal of Clinical Microbiology, 2014, 52, 3399-3401.	3.9	19
97	Decreased Ceftriaxone Susceptibility in Emerging (35B and 6C) and Persisting (19A) Streptococcus pneumoniae Serotypes in the United States, 2011-2012: Ceftaroline Remains Active In Vitro among Î²-Lactam Agents. Antimicrobial Agents and Chemotherapy, 2014, 58, 4923-4927.	3.2	19
98	Ceftaroline Activity Tested Against Bacterial Isolates From Pediatric Patients. Pediatric Infectious Disease Journal, 2014, 33, 837-842.	2.0	20
99	Relationship between Ceftolozane-Tazobactam Exposure and Selection for Pseudomonas aeruginosa Resistance in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2014, 58, 6024-6031.	3.2	39
100	Frequency of fks Mutations among Candida glabrata Isolates from a 10-Year Global Collection of Bloodstream Infection Isolates. Antimicrobial Agents and Chemotherapy, 2014, 58, 577-580.	3.2	67
101	Frequency of occurrence and antimicrobial susceptibility of Gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009â€“2011). Journal of Chemotherapy, 2014, 26, 133-138.	1.5	34
102	Antimicrobial Activity of Ceftaroline Tested against Drug-Resistant Subsets of Streptococcus pneumoniae from U.S. Medical Centers. Antimicrobial Agents and Chemotherapy, 2014, 58, 2468-2471.	3.2	21
103	Summary of Linezolid Activity and Resistance Mechanisms Detected during the 2012 LEADER Surveillance Program for the United States. Antimicrobial Agents and Chemotherapy, 2014, 58, 1243-1247.	3.2	44
104	Ceftobiprole Activity against over 60,000 Clinical Bacterial Pathogens Isolated in Europe, Turkey, and Israel from 2005 to 2010. Antimicrobial Agents and Chemotherapy, 2014, 58, 3882-3888.	3.2	62
105	Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types. International Journal of Antimicrobial Agents, 2014, 43, 323-327.	2.5	22
106	Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE program, 2009â€“2011. Diagnostic Microbiology and Infectious Disease, 2014, 78, 437-442.	1.8	15
107	Variation in Potency and Spectrum of Tigecycline Activity against Bacterial Strains from U.S. Medical Centers since Its Approval for Clinical Use (2006 to 2012). Antimicrobial Agents and Chemotherapy, 2014, 58, 2274-2280.	3.2	41
108	Resistance surveillance program report for selected European nations (2011). Diagnostic Microbiology and Infectious Disease, 2014, 78, 429-436.	1.8	78

#	Article	IF	Citations
109	Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011). Brazilian Journal of Infectious Diseases, 2014, 18, 187-195.	0.6	18
110	Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009â€“2011). Diagnostic Microbiology and Infectious Disease, 2014, 78, 422-428.	1.8	23
111	Linezolid update: Stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. Drug Resistance Updates, 2014, 17, 1-12.	14.4	195
112	Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009â€“2011). Diagnostic Microbiology and Infectious Disease, 2014, 78, 443-448.	1.8	184
113	Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010â€“2012). Diagnostic Microbiology and Infectious Disease, 2014, 78, 449-456.	1.8	19
114	Detection of NDM-1-producing Enterobacteriaceae in Romania: report of the SENTRY Antimicrobial Surveillance Program. Journal of Medical Microbiology, 2014, 63, 483-484.	1.8	4
115	Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries. Journal of Antimicrobial Chemotherapy, 2014, 69, 1804-1814.	3.0	173
116	Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program: report of linezolid activity over 9 years (2004-12). Journal of Antimicrobial Chemotherapy, 2014, 69, 1582-1588.	3.0	67
117	Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Organisms Collected from U.S. Medical Centers in 2012. Antimicrobial Agents and Chemotherapy, 2014, 58, 1684-1692.	3.2	129
118	Use of Micafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 3,764 Clinical Isolates of Candida by Use of CLSI Methods and Interpretive Criteria. Journal of Clinical Microbiology, 2014, 52, 108-114.	3.9	59
119	Regional data analysis of Candida nonâ€albicans strains collected in United States medical sites over a 6â€year period, 2006â€“2011. Mycoses, 2014, 57, 602-611.	4.0	82
120	Use of Anidulafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 4,290 Clinical Isolates of Candida by Using CLSI Methods and Interpretive Criteria. Journal of Clinical Microbiology, 2014, 52, 3223-3229.	3.9	44
121	Mutation-Driven Î²-Lactam Resistance Mechanisms among Contemporary Ceftazidime-Nonsusceptible Pseudomonas aeruginosa Isolates from U.S. Hospitals. Antimicrobial Agents and Chemotherapy, 2014, 58, 6844-6850.	3.2	118
122	Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections. International Journal of Antimicrobial Agents, 2014, 44, 320-326.	2.5	64
123	Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011â€“12). Journal of Antimicrobial Chemotherapy, 2014, 69, 2713-2722.	3.0	130
124	Isavuconazole and Nine Comparator Antifungal Susceptibility Profiles for Common and Uncommon Candida Species Collected in 2012: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values. Mycopathologia, 2014, 178, 1-9.	3.1	42
125	Evaluation of Clonality and Carbapenem Resistance Mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus Complex and Enterobacteriaceae Isolates Collected in European and Mediterranean Countries and Detection of Two Novel Î²-Lactamases, GES-22 and VIM-35. Antimicrobial Agents and Chemotherapy, 2014, 58, 7358-7366.	3.2	53
126	Contemporary Diversity of Î²-Lactamases among Enterobacteriaceae in the Nine U.S. Census Regions and Ceftazidime-Avibactam Activity Tested against Isolates Producing the Most Prevalent Î²-Lactamase Groups. Antimicrobial Agents and Chemotherapy, 2014, 58, 833-838.	3.2	170

#	Article	IF	Citations
127	Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). International Journal of Antimicrobial Agents, 2014, 43, 533-539.	2.5	123
128	Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: Summary of 8 years of a Worldwide Surveillance Programme (2005â€“2012). International Journal of Antimicrobial Agents, 2014, 43, 465-469.	2.5	76
129	Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 Systemically active antifungal agents when tested against Candida spp.. Diagnostic Microbiology and Infectious Disease, 2014, 79, 198-204.	1.8	64
130	Regional pooling of national data from a small number of sites can be misleading: maybe yes? But data can be complimentary to other studies and valuable to infectious disease physicians!. Diagnostic Microbiology and Infectious Disease, 2014, 80, 91-92.	1.8	0
131	Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). Journal of Infection, 2014, 69, 266-277.	3.3	75
132	Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009â€“2012. International Journal of Antimicrobial Agents, 2014, 43, 328-334.	2.5	194
133	Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012). Journal of Antimicrobial Chemotherapy, 2014, 69, 1589-1598.	3.0	61
134	Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine. Diagnostic Microbiology and Infectious Disease, 2014, 80, 19-25.	1.8	45
135	Update of contemporary antimicrobial resistance rates across China: reference testing results for 12 medical centers (2011). Diagnostic Microbiology and Infectious Disease, 2013, 77, 258-266.	1.8	26
136	Determination of disk diffusion and MIC quality control guidelines for GSK2251052: a novel boron-containing antibacterial. Diagnostic Microbiology and Infectious Disease, 2013, 75, 437-439.	1.8	9
137	Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011). Brazilian Journal of Infectious Diseases, 2013, 17, 672-681.	0.6	101
138	Reply to Nation et al. Clinical Infectious Diseases, 2013, 57, 1657-1658.	5.8	1
139	Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance. Journal of Clinical Microbiology, 2013, 51, 2571-2581.	3.9	209
140	10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America. Clinical Infectious Diseases, 2013, 56, 1685-1694.	5.8	612
141	Polymyxins: Wisdom Does Not Always Come With Age. Clinical Infectious Diseases, 2013, 57, 877-883.	5.8	38
142	Regional Resistance Surveillance Program Results for 12 Asia-Pacific Nations (2011). Antimicrobial Agents and Chemotherapy, 2013, 57, 5721-5726.	3.2	74
143	Update on the prevalence and genetic characterization of NDM-1â€“producing Enterobacteriaceae in Indian hospitals during 2010. Diagnostic Microbiology and Infectious Disease, 2013, 75, 210-213.	1.8	21
144	An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011. Diagnostic Microbiology and Infectious Disease, 2013, 76, 206-213.	1.8	57

#	Article	IF	Citations
145	Contemporary tetracycline susceptibility testing: doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing Gram-positive pathogens. Diagnostic Microbiology and Infectious Disease, 2013, 76, 69-72.	1.8	19
146	Prevalence of Î²-Lactamase-Encoding Genes among Enterobacteriaceae Bacteremia Isolates Collected in 26 U.S. Hospitals: Report from the SENTRY Antimicrobial Surveillance Program (2010). Antimicrobial Agents and Chemotherapy, 2013, 57, 3012-3020.	3.2	100
147	Educational antimicrobial susceptibility testing as a critical component of microbiology laboratory proficiency programs: American Proficiency Institute results for 2007â€“2011. Diagnostic Microbiology and Infectious Disease, 2013, 75, 357-360.	1.8	9
148	Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagnostic Microbiology and Infectious Disease, 2013, 75, 304-307.	1.8	100
149	Surveillance of dalbavancin potency and spectrum in the United States (2012). Diagnostic Microbiology and Infectious Disease, 2013, 76, 122-123.	1.8	29
150	Comparative potencies of contemporary generic vancomycin lot: in vitro assay results from nine products and a reference reagent-grade sample. Diagnostic Microbiology and Infectious Disease, 2013, 76, 237-238.	1.8	3
151	Comprehensive update of dalbavancin activity when tested against uncommonly isolated streptococci, Corynebacterium spp., Listeria monocytogenes, and Micrococcus spp. (1357 strains). Diagnostic Microbiology and Infectious Disease, 2013, 76, 239-240.	1.8	18
152	Background and Rationale for Revised Clinical and Laboratory Standards Institute Interpretive Criteria (Breakpoints) for Enterobacteriaceae andPseudomonas aeruginosa:I. Cephalosporins and Aztreonam. Clinical Infectious Diseases, 2013, 56, 1301-1309.	5.8	132
153	Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011). Diagnostic Microbiology and Infectious Disease, 2013, 76, 217-221.	1.8	64
154	More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USA. Diagnostic Microbiology and Infectious Disease, 2013, 76, 110-112.	1.8	5
155	Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010). International Journal of Antimicrobial Agents, 2013, 41, 337-342.	2.5	30
156	Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010). Diagnostic Microbiology and Infectious Disease, 2013, 76, 61-68.	1.8	27
157	Trends in Klebsiella pneumoniae carbapenemase-positive K. pneumoniae in US hospitals: report from the 2007â€“2009 SENTRY Antimicrobial Surveillance Program. Diagnostic Microbiology and Infectious Disease, 2013, 76, 356-360.	1.8	50
158	Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria. Diagnostic Microbiology and Infectious Disease, 2013, 75, 402-405.	1.8	11
159	Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). Diagnostic Microbiology and Infectious Disease, 2013, 75, 86-88.	1.8	15
160	Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate Î²-lactam markers to predict ceftaroline activity against clinically indicated species. Diagnostic Microbiology and Infectious Disease, 2013, 75, 89-93.	1.8	10
161	Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998â€“2011). Diagnostic Microbiology and Infectious Disease, 2013, 75, 107-109.	1.8	80
162	Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011). Diagnostic Microbiology and Infectious Disease, 2013, 75, 417-422.	1.8	49

#	Article	IF	Citations
163	Linezolid Surveillance Results for the United States: LEADER Surveillance Program 2011. Antimicrobial Agents and Chemotherapy, 2013, 57, 1077-1081.	3.2	48
164	IMP-33, a New IMP Variant Detected in Pseudomonas aeruginosa from Sicily. Antimicrobial Agents and Chemotherapy, 2013, 57, 6401-6403.	3.2	5
165	Antimicrobial Activity of Ceftaroline Tested against Staphylococci with Reduced Susceptibility to Linezolid, Daptomycin, or Vancomycin from U.S. Hospitals, 2008 to 2011. Antimicrobial Agents and Chemotherapy, 2013, 57, 3178-3181.	3.2	43
166	Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012). Antimicrobial Agents and Chemotherapy, 2013, 57, 6305-6310.	3.2	177
167	Antimicrobial Activity of Ceftaroline-Avibactam Tested against Clinical Isolates Collected from U.S. Medical Centers in 2010-2011. Antimicrobial Agents and Chemotherapy, 2013, 57, 1982-1988.	3.2	37
168	Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST). Journal of Antimicrobial Chemotherapy, 2013, 68, 858-863.	3.0	87
169	Pharmacological Basis of Î²-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane. Antimicrobial Agents and Chemotherapy, 2013, 57, 5924-5930.	3.2	62
170	Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in an In Vitro Infection Model. Antimicrobial Agents and Chemotherapy, 2013, 57, 2809-2814.	3.2	79
171	Treatment of Methicillin-Susceptible Staphylococcus aureus Osteoarticular and Prosthetic Joint Infections: Using the Oxacillin Minimum Inhibitory Concentration to Guide Appropriate Ceftriaxone Use. Clinical Infectious Diseases, 2013, 57, 161-162.	5.8	13
172	Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens. Journal of Antimicrobial Chemotherapy, 2013, 68, 636-639.	3.0	27
173	Potency and Spectrum of Activity of AN3365, a Novel Boron-Containing Protein Synthesis Inhibitor, Tested against Clinical Isolates of Enterobacteriaceae and Nonfermentative Gram-Negative Bacilli. Antimicrobial Agents and Chemotherapy, 2013, 57, 2849-2857.	3.2	37
174	In Vitro Activity of a New Oral Glucan Synthase Inhibitor (MK-3118) Tested against Aspergillus spp. by CLSI and EUCAST Broth Microdilution Methods. Antimicrobial Agents and Chemotherapy, 2013, 57, 1065-1068.	3.2	80
175	Daptomycin Activity against Uncommonly Isolated Streptococcal and Other Gram-Positive Species Groups. Antimicrobial Agents and Chemotherapy, 2013, 57, 6378-6380.	3.2	13
176	Streptococcus sanguinis Isolate Displaying a Phenotype with Cross-Resistance to Several rRNA-Targeting Agents. Journal of Clinical Microbiology, 2013, 51, 2728-2731.	3.9	16
177	Antimicrobial Activity of the Pleuromutilin Antibiotic BC-3781 against Bacterial Pathogens Isolated in the SENTRY Antimicrobial Surveillance Program in 2010. Antimicrobial Agents and Chemotherapy, 2013, 57, 4489-4495.	3.2	73
178	Evaluation of Vancomycin Susceptibility Testing for Methicillin-Resistant Staphylococcus aureus: Comparison of Etest and Three Automated Testing Methods. Journal of Clinical Microbiology, 2013, 51, 2077-2081.	3.9	73
179	Candida guilliermondii and Other Species of Candida Misidentified as Candida famata: Assessment by Vitek 2, DNA Sequencing Analysis, and Matrix-Assisted Laser Desorption Ionizationâ€“Time of Flight Mass Spectrometry in Two Global Antifungal Surveillance Programs. Journal of Clinical Microbiology, 2013, 51, 117-124.	3.9	88
180	In Vitro Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds. Journal of Clinical Microbiology, 2013, 51, 2608-2616.	3.9	75

#	Article	IF	Citations
181	Rapid Expansion of KPC-2-Producing Klebsiella pneumoniae Isolates in Two Texas Hospitals due to Clonal Spread of ST258 and ST307 Lineages. Microbial Drug Resistance, 2013, 19, 295-297.	2.0	54
182	The Genetic Environment of the cfr Gene and the Presence of Other Mechanisms Account for the Very High Linezolid Resistance of Staphylococcus epidermidis Isolate 426-3147L. Antimicrobial Agents and Chemotherapy, 2013, 57, 1173-1179.	3.2	36
183	Dissemination of a pSCFS3-Like cfr -Carrying Plasmid in Staphylococcus aureus and Staphylococcus epidermidis Clinical Isolates Recovered from Hospitals in Ohio. Antimicrobial Agents and Chemotherapy, 2013, 57, 2923-2928.	3.2	40
184	Relationship between Ceftolozane-Tazobactam Exposure and Drug Resistance Amplification in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2013, 57, 4134-4138.	3.2	38
185	Klebsiella pneumoniae Carbapenemase-Producing Enterobacteriaceae Testing Susceptible to Cefepime by Reference Methods. Journal of Clinical Microbiology, 2013, 51, 2388-2390.	3.9	7
186	Commentary. Pediatric Infectious Disease Journal, 2013, 32, 970-971.	2.0	3
187	AWARE Ceftaroline Surveillance Program (2008â€“2010): Trends in Resistance Patterns Among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clinical Infectious Diseases, 2012, 55, S187-S193.	5.8	68
188	Summary of Ceftaroline Activity against Pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program. Antimicrobial Agents and Chemotherapy, 2012, 56, 2933-2940.	3.2	71
189	Pharmacodynamics of Î²-Lactamase Inhibition by NXL104 in Combination with Ceftaroline: Examining Organisms with Multiple Types of Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2012, 56, 258-270.	3.2	66
190	Worldwide Appraisal and Update (2010) of Telavancin Activity Tested against a Collection of Gram-Positive Clinical Pathogens from Five Continents. Antimicrobial Agents and Chemotherapy, 2012, 56, 3999-4004.	3.2	35
191	Oritavancin Activity against Vancomycin-Susceptible and Vancomycin-Resistant Enterococci with Molecularly Characterized Glycopeptide Resistance Genes Recovered from Bacteremic Patients, 2009-2010. Antimicrobial Agents and Chemotherapy, 2012, 56, 1639-1642.	3.2	31
192	Oritavancin Microbiologic Features and Activity Results From the Surveillance Program in the United States. Clinical Infectious Diseases, 2012, 54, S203-S213.	5.8	39
193	Disk Diffusion and MIC Quality Control Ranges for BC-3205 and BC-3781, Two Novel Pleuromutilin Antibiotics. Journal of Clinical Microbiology, 2012, 50, 3361-3364.	3.9	13
194	Activity Analyses of Staphylococcal Isolates From Pediatric, Adult, and Elderly Patients: AWARE Ceftaroline Surveillance Program. Clinical Infectious Diseases, 2012, 55, S181-S186.	5.8	30
195	Ceftaroline Potency Among 9 US Census Regions: Report From the 2010 AWARE Program. Clinical Infectious Diseases, 2012, 55, S194-S205.	5.8	16
196	Antimicrobial Activity of the Investigational Pleuromutilin Compound BC-3781 Tested against Gram-Positive Organisms Commonly Associated with Acute Bacterial Skin and Skin Structure Infections. Antimicrobial Agents and Chemotherapy, 2012, 56, 1619-1623.	3.2	73
197	Challenges in Assessing Microbial Susceptibility and Predicting Clinical Response to Newer-Generation Fluoroquinolones. Journal of Ocular Pharmacology and Therapeutics, 2012, 28, 3-11.	1.4	22
198	In Vitro Activity of Ceftaroline Against Multidrug-Resistant Staphylococcus aureus and Streptococcus pneumoniae: A Review of Published Studies and the AWARE Surveillance Program (2008â€“2010). Clinical Infectious Diseases, 2012, 55, S206-S214.	5.8	78

#	Article	IF	Citations
199	Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular Methods. Antimicrobial Agents and Chemotherapy, 2012, 56, 352-357.	3.2	82
200	Expansion of Clonal Complex 258 KPC-2-Producing Klebsiella pneumoniae in Latin American Hospitals: Report of the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy, 2012, 56, 1668-1669.	3.2	39
201	Unmet Needs and Prospects for Oritavancin in the Management of Vancomycin-Resistant Enterococcal Infections. Clinical Infectious Diseases, 2012, 54, S233-S238.	5.8	48
202	ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries. Journal of Chemotherapy, 2012, 24, 328-337.	1.5	18
203	Characterization of Methicillin-Resistant Staphylococcus aureus Strains Recovered from a Phase IV Clinical Trial for Linezolid versus Vancomycin for Treatment of Nosocomial Pneumonia. Journal of Clinical Microbiology, 2012, 50, 3694-3702.	3.9	34
204	Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs). Journal of Antimicrobial Chemotherapy, 2012, 67, 1170-1175.	3.0	81
205	Significance of Molecular Identification and Antifungal Susceptibility of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance Programme. Mycopathologia, 2012, 174, 259-271.	3.1	72
206	Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007â€“2009). Diagnostic Microbiology and Infectious Disease, 2012, 72, 113-117.	1.8	21
207	Evaluation of quinolone resistanceâ€“determining region mutations and efflux pump expression in Neisseria meningitidis resistant to fluoroquinolones. Diagnostic Microbiology and Infectious Disease, 2012, 72, 263-266.	1.8	15
208	Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative Staphylococcus. Diagnostic Microbiology and Infectious Disease, 2012, 73, 212-214.	1.8	22
209	Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008â€“2010). Diagnostic Microbiology and Infectious Disease, 2012, 73, 354-360.	1.8	222
210	Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia. International Journal of Antimicrobial Agents, 2012, 39, 321-325.	2.5	12
211	LEADER Surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). Diagnostic Microbiology and Infectious Disease, 2012, 74, 54-61.	1.8	45
212	Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymyxin B and colistin. Diagnostic Microbiology and Infectious Disease, 2012, 74, 412-414.	1.8	65
213	Molecular characterization of vancomycin-resistant Enterococcus spp. clinical isolates recovered from hospitalized patients among several medical institutions in China. Diagnostic Microbiology and Infectious Disease, 2012, 74, 399-403.	1.8	23
214	Activity of Ceftaroline-Avibactam Tested against Gram-Negative Organism Populations, including Strains Expressing One or More Î²-Lactamases and Methicillin-Resistant Staphylococcus aureus Carrying Various Staphylococcal Cassette Chromosome mec Types. Antimicrobial Agents and Chemotherapy, 2012, 56, 4779-4785.	3.2	70
215	Candida glabrata: Multidrug Resistance and Increased Virulence in a Major Opportunistic Fungal Pathogen. Current Fungal Infection Reports, 2012, 6, 154-164.	2.6	8
216	Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. Journal of Antimicrobial Chemotherapy, 2012, 67, 1321-1324.	3.0	97

#	Article	IF	Citations
217	Geographic Variations in Species Distribution and Echinocandin and Azole Antifungal Resistance Rates among Candida Bloodstream Infection Isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). Journal of Clinical Microbiology, 2011, 49, 396-399.	3.9	192
218	Susceptibility of Klebsiella spp. to colistin and polymyxin B: results from the SENTRY Antimicrobial Surveillance Program (2006â€“2009). International Journal of Antimicrobial Agents, 2011, 37, 174-175.	2.5	16
219	Comparative activity of linezolid against respiratory tract infection isolates of Staphylococcus aureus: an 11-year report from the SENTRY Antimicrobial Surveillance Program. International Journal of Antimicrobial Agents, 2011, 37, 584-585.	2.5	4
220	Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008â€“2009). International Journal of Antimicrobial Agents, 2011, 38, 65-69.	2.5	216
221	Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007â€“09). Journal of Antimicrobial Chemotherapy, 2011, 66, 1409-1411.	3.0	65
222	Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. Journal of Antimicrobial Chemotherapy, 2011, 66, iii69-iii80.	3.0	43
223	Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagnostic Microbiology and Infectious Disease, 2011, 69, 45-50.	1.8	96
224	Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005â€“2009). Diagnostic Microbiology and Infectious Disease, 2011, 69, 223-227.	1.8	31
225	Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005â€“2010). Diagnostic Microbiology and Infectious Disease, 2011, 70, 412-416.	1.8	44
226	In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method. Diagnostic Microbiology and Infectious Disease, 2011, 71, 167-170.	1.8	53
227	Update on the telavancin activity tested against European staphylococcal clinical isolates (2009â€“2010). Diagnostic Microbiology and Infectious Disease, 2011, 71, 93-97.	1.8	22
228	Plasmid-borne vga(A)-encoding gene in methicillin-resistant Staphylococcus aureus ST398 recovered from swine and a swine farmer in the United States. Diagnostic Microbiology and Infectious Disease, 2011, 71, 177-180.	1.8	18
229	Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method. Diagnostic Microbiology and Infectious Disease, 2011, 71, 252-259.	1.8	56
230	Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 sentry antimicrobial surveillance program. Diagnostic Microbiology and Infectious Disease, 2011, 71, 415-420.	1.8	8
231	Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). Journal of Antimicrobial Chemotherapy, 2011, 66, 2070-2074.	3.0	295
232	Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins. Current Fungal Infection Reports, 2011, 5, 120-127.	2.6	4
233	LEADER Program Results for 2009: an Activity and Spectrum Analysis of Linezolid Using 6,414 Clinical Isolates from 56 Medical Centers in the United States. Antimicrobial Agents and Chemotherapy, 2011, 55, 3684-3690.	3.2	79
234	Early Dissemination of NDM-1- and OXA-181-Producing Enterobacteriaceae in Indian Hospitals: Report from the SENTRY Antimicrobial Surveillance Program, 2006-2007. Antimicrobial Agents and Chemotherapy, 2011, 55, 1274-1278.	3.2	303

#	Article	IF	Citations
235	Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods. Journal of Antimicrobial Chemotherapy, 2011, 66, 2581-2584.	3.0	46
236	In Vitro Antimicrobial Findings for Fusidic Acid Tested Against Contemporary (2008â€“2009) Gram-Positive Organisms Collected in the United States. Clinical Infectious Diseases, 2011, 52, S477-S486.	5.8	38
237	OXA-163, an OXA-48-Related Class D Î²-Lactamase with Extended Activity Toward Expanded-Spectrum Cephalosporins. Antimicrobial Agents and Chemotherapy, 2011, 55, 2546-2551.	3.2	128
238	Comment on: Role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo-Â-lactamases. Journal of Antimicrobial Chemotherapy, 2011, 66, 684-685.	3.0	12
239	JNJ-Q2, a New Fluoroquinolone with PotentIn VitroActivity against Staphylococcus aureus, Including Methicillin- and Fluoroquinolone-Resistant Strains. Antimicrobial Agents and Chemotherapy, 2011, 55, 3631-3634.	3.2	21
240	Candida Bloodstream Infections: Comparison of Species Distributions and Antifungal Resistance Patterns in Community-Onset and Nosocomial Isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrobial Agents and Chemotherapy, 2011, 55, 561-566.	3.2	204
241	Triazole and Echinocandin MIC Distributions with Epidemiological Cutoff Values for Differentiation of Wild-Type Strains from Non-Wild-Type Strains of Six Uncommon Species of Candida. Journal of Clinical Microbiology, 2011, 49, 3800-3804.	3.9	59
242	Determination of Disk Diffusion and MIC Quality Control Guidelines for JNJ-Q2, a Novel Quinolone. Journal of Clinical Microbiology, 2011, 49, 3009-3011.	3.9	1
243	In Vitro Activity of a Novel Broad-Spectrum Antifungal, E1210, Tested against Aspergillus spp. Determined by CLSI and EUCAST Broth Microdilution Methods. Antimicrobial Agents and Chemotherapy, 2011, 55, 5155-5158.	3.2	66
244	Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes. Antimicrobial Agents and Chemotherapy, 2011, 55, 2390-2394.	3.2	112
245	The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009). Journal of Infection, 2010, 61, 476-483.	3.3	33
246	Binaphthylâ€Based Dicationic Peptoids with Therapeutic Potential. Angewandte Chemie - International Edition, 2010, 49, 537-540.	13.8	58
247	The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). Journal of Infection, 2010, 60, 440-451.	3.3	28
248	Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008). Pathology, 2010, 42, 470-473.	0.6	15
249	Potency of Anidulafungin Compared to Nine Other Antifungal Agents Tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Results from the Global SENTRY Antimicrobial Surveillance Program (2008). Journal of Clinical Microbiology, 2010, 48, 2984-2987.	3.9	29
250	Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia. Journal of Antimicrobial Chemotherapy, 2010, 65, 2396-2404.	3.0	35
251	In Vitro Activity of Telavancin against a Contemporary Worldwide Collection of Staphylococcus aureus Isolates. Antimicrobial Agents and Chemotherapy, 2010, 54, 2704-2706.	3.2	27
252	Clonal Dissemination of Klebsiella pneumoniae Carbapenemase KPC-3 in Long Beach, California. Journal of Clinical Microbiology, 2010, 48, 623-625.	3.9	15

#	Article	IF	Citations
253	Fixed-Ratio Combination Testing of an Echinocandin, Anidulafungin, and an Azole, Voriconazole, against 1,467 Candida Species Isolates. Antimicrobial Agents and Chemotherapy, 2010, 54, 4041-4043.	3.2	3
254	Fusidic Acid Resistance Rates and Prevalence of Resistance Mechanisms among Staphylococcus spp. Isolated in North America and Australia, 2007-2008. Antimicrobial Agents and Chemotherapy, 2010, 54, 3614-3617.	3.2	77
255	CEM-101 Activity against Gram-Positive Organisms. Antimicrobial Agents and Chemotherapy, 2010, 54, 2182-2187.	3.2	37
256	Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. Journal of Antimicrobial Chemotherapy, 2010, 65, iv17-iv31.	3.0	61
257	Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy. Journal of Antimicrobial Chemotherapy, 2010, 65, 2329-2335.	3.0	126
258	Antimicrobial Susceptibilities of a Worldwide Collection of Stenotrophomonas maltophilia Isolates Tested against Tigecycline and Agents Commonly Used for S. maltophilia Infections. Antimicrobial Agents and Chemotherapy, 2010, 54, 2735-2737.	3.2	93
259	Performance of Fusidic Acid (CEM-102) Susceptibility Testing Reagents: Broth Microdilution, Disk Diffusion, and Etest Methods as Applied to Staphylococcus aureus. Journal of Clinical Microbiology, 2010, 48, 972-976.	3.9	13
260	Antimicrobial Susceptibility Patterns of KPC-Producing or CTX-M-Producing Enterobacteriaceae. Microbial Drug Resistance, 2010, 16, 61-65.	2.0	45
261	Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains. Antimicrobial Agents and Chemotherapy, 2010, 54, 2655-2659.	3.2	112
262	MIC Quality Control Guidelines and Disk Diffusion Test Optimization for CEM-101, a Novel Fluoroketolide. Journal of Clinical Microbiology, 2010, 48, 1470-1473.	3.9	2
263	Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid. Journal of Clinical Microbiology, 2010, 48, 568-574.	3.9	40
264	Activity of Ceftaroline against Recent Emerging Serotypes of Streptococcus pneumoniae in the United States. Antimicrobial Agents and Chemotherapy, 2010, 54, 2716-2719.	3.2	67
265	First Report of Staphylococcal Clinical Isolates in Mexico with Linezolid Resistance Caused by cfr : Evidence of In Vivo cfr Mobilization. Journal of Clinical Microbiology, 2010, 48, 3041-3043.	3.9	56
266	Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada. International Journal of Antimicrobial Agents, 2010, 35, 282-287.	2.5	29
267	Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. International Journal of Antimicrobial Agents, 2010, 35, 537-543.	2.5	43
268	Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres. International Journal of Antimicrobial Agents, 2010, 36, 28-32.	2.5	52
269	Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. International Journal of Antimicrobial Agents, 2010, 36, 197-204.	2.5	82
270	Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008). Journal of Antimicrobial Chemotherapy, 2010, 65, 1353-1358.	3.0	89

#	Article	IF	Citations
271	Microbial Etiologies of Hospitalâ€Acquired Bacterial Pneumonia and Ventilatorâ€Associated Bacterial Pneumonia. Clinical Infectious Diseases, 2010, 51, S81-S87.	5.8	570
272	Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 Î¼g/mL isolated in the United States and European hospitals (2006â€“2008). Diagnostic Microbiology and Infectious Disease, 2010, 66, 329-331.	1.8	19
273	CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. Diagnostic Microbiology and Infectious Disease, 2010, 66, 393-401.	1.8	48
274	Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102). Diagnostic Microbiology and Infectious Disease, 2010, 66, 301-307.	1.8	20
275	Escherichia coli resistance to quinolones at a comprehensive cancer center. Diagnostic Microbiology and Infectious Disease, 2010, 67, 266-269.	1.8	27
276	Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results. Diagnostic Microbiology and Infectious Disease, 2010, 67, 359-368.	1.8	31
277	Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagnostic Microbiology and Infectious Disease, 2010, 68, 251-258.	1.8	52
278	Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008â€“2009). Diagnostic Microbiology and Infectious Disease, 2010, 68, 278-283.	1.8	141
279	Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005â€“2009). Diagnostic Microbiology and Infectious Disease, 2010, 68, 307-311.	1.8	41
280	Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998â€“2009). Diagnostic Microbiology and Infectious Disease, 2010, 68, 334-336.	1.8	54
281	Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 ZyvoxÂ® Annual Appraisal of Potency and Spectrum program. Diagnostic Microbiology and Infectious Disease, 2010, 68, 459-467.	1.8	39
282	In Vitro Activity of Ceftaroline Alone and in Combination against Clinical Isolates of Resistant Gram-Negative Pathogens, Including Î²-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2009, 53, 2360-2366.	3.2	51
283	Rationale for Revised Penicillin Susceptibility Breakpoints versusStreptococcus pneumoniae:Coping with Antimicrobial Susceptibility in an Era of Resistance. Clinical Infectious Diseases, 2009, 48, 1596-1600.	5.8	163
284	Daptomycin Activity Tested Against Linezolid-Nonsusceptible Gram-Positive Clinical Isolates. Microbial Drug Resistance, 2009, 15, 245-249.	2.0	14
285	Nine-Hospital Study Comparing Broth Microdilution and Etest Method Results for Vancomycin and Daptomycin against Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2009, 53, 3162-3165.	3.2	87
286	First Descriptions of bla _{KPC} in Raoultella spp. (R. planticola and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Clinical Microbiology, 2009, 47, 4129-4130.	3.9	92
287	Evaluation of Vancomycin and Daptomycin Potency Trends (MIC Creep) against Methicillin-Resistant Staphylococcus aureus Isolates Collected in Nine U.S. Medical Centers from 2002 to 2006. Antimicrobial Agents and Chemotherapy, 2009, 53, 4127-4132.	3.2	113
288	Activity of Contemporary Antifungal Agents, Including the Novel Echinocandin Anidulafungin, Tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). Journal of Clinical Microbiology, 2009, 47, 1942-1946.	3.9	66

#	Article	IF	Citations
289	Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. Journal of Antimicrobial Chemotherapy, 2009, 64, 1024-1028.	3.0	56
290	TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens. Journal of Antimicrobial Chemotherapy, 2009, 63, 716-720.	3.0	37
291	Codetection of bla _{OXA-23} -Like Gene (bla _{OXA-133}) and bla _{OXA-58} in Acinetobacter radioresistens : Report from the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy, 2009, 53, 843-844.	3.2	16
292	Antimicrobial Activities of Piperacillin-Tazobactam against Haemophilus influenzae Isolates, Including Î²-Lactamase-Negative Ampicillin-Resistant and Î²-Lactamase-Positive Amoxicillin-Clavulanate-Resistant Isolates, and Mutations in Their Quinolone Resistance-Determining Regions. Antimicrobial Agents and Chemotherapy, 2009, 53, 4225-4230.	3.2	24
293	Carbapenem Resistance among Pseudomonas aeruginosa Strains from India: Evidence for Nationwide Endemicity of Multiple Metallo-Î²-Lactamase Clones (VIM-2, -5, -6, and -11 and the Newly) Tj ETQq1 1 0.784314 rgBT /Ove	3.2	84
294	Activities of Dalbavancin against a Worldwide Collection of 81,673 Gram-Positive Bacterial Isolates. Antimicrobial Agents and Chemotherapy, 2009, 53, 1260-1263.	3.2	76
295	Comparison of 2002â€“2006 OPTAMA Programs for US Hospitals: Focus on Gram-Negative Resistance. Annals of Pharmacotherapy, 2009, 43, 220-227.	1.9	35
296	Case Report of Aurantimonas altamirensis Bloodstream Infection. Journal of Clinical Microbiology, 2009, 47, 514-515.	3.9	17
297	A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.. Diagnostic Microbiology and Infectious Disease, 2009, 63, 233-236.	1.8	22
298	Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007). Diagnostic Microbiology and Infectious Disease, 2009, 64, 177-184.	1.8	23
299	Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003â€“2007). Diagnostic Microbiology and Infectious Disease, 2009, 63, 440-446.	1.8	14
300	In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens. Diagnostic Microbiology and Infectious Disease, 2009, 63, 434-439.	1.8	9
301	Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.. Diagnostic Microbiology and Infectious Disease, 2009, 63, 426-433.	1.8	63
302	ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Diagnostic Microbiology and Infectious Disease, 2009, 64, 191-201.	1.8	66
303	Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots. Diagnostic Microbiology and Infectious Disease, 2009, 65, 319-322.	1.8	19
304	Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007â€“2008). Diagnostic Microbiology and Infectious Disease, 2009, 65, 158-162.	1.8	90
305	Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997â€“2007). Diagnostic Microbiology and Infectious Disease, 2009, 65, 331-334.	1.8	41
306	Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999â€“2008). Diagnostic Microbiology and Infectious Disease, 2009, 65, 414-426.	1.8	156

#	Article	IF	Citations
307	ZyvoxÂ® Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. Diagnostic Microbiology and Infectious Disease, 2009, 65, 404-413.	1.8	73
308	Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagnostic Microbiology and Infectious Disease, 2009, 65, 392-403.	1.8	76
309	Activity of daptomycin against Gram-positive bacterial isolates from Indian medical centres (2006â€“2007). International Journal of Antimicrobial Agents, 2009, 34, 497-499.	2.5	12
310	Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients. International Journal of Infectious Diseases, 2009, 13, 291-295.	3.3	8
311	Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagnostic Microbiology and Infectious Disease, 2008, 60, 433-436.	1.8	41
312	In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus. Diagnostic Microbiology and Infectious Disease, 2008, 60, 399-403.	1.8	21
313	In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (ZosynÂ®, Wyeth) formulation. Diagnostic Microbiology and Infectious Disease, 2008, 61, 76-79.	1.8	30
314	Antimicrobial activity of cefditoren tested against contemporary (2004â€“2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States. Diagnostic Microbiology and Infectious Disease, 2008, 61, 240-244.	1.8	9
315	Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006). Diagnostic Microbiology and Infectious Disease, 2008, 61, 235-239.	1.8	42
316	Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagnostic Microbiology and Infectious Disease, 2008, 61, 203-213.	1.8	55
317	Antimicrobial activity of ceftobiprole, a novel antiâ€“methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005â€“2006). Diagnostic Microbiology and Infectious Disease, 2008, 61, 86-95.	1.8	90
318	Pharmacokinetic and pharmacodynamic profile of ceftobiprole. Diagnostic Microbiology and Infectious Disease, 2008, 61, 96-102.	1.8	30
319	Proposed quality control ranges for 2-Î¼g anidulafungin disk diffusion testing and ability of the method to detect strains with elevated echinocandin MIC values. Diagnostic Microbiology and Infectious Disease, 2008, 62, 474-477.	1.8	0
320	United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagnostic Microbiology and Infectious Disease, 2008, 62, 416-426.	1.8	80
321	Serotype Replacement and Multiple Resistance in Streptococcus pneumoniae After the Introduction of the Conjugate Pneumococcal Vaccine. Microbial Drug Resistance, 2008, 14, 101-107.	2.0	73
322	First Report of cfr -Mediated Resistance to Linezolid in Human Staphylococcal Clinical Isolates Recovered in the United States. Antimicrobial Agents and Chemotherapy, 2008, 52, 2244-2246.	3.2	203
323	Antimicrobial Activities of Tigecycline and Other Broad-Spectrum Antimicrobials Tested against Serine Carbapenemase- and Metallo-Î²-Lactamase-Producing Enterobacteriaceae : Report from the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy, 2008, 52, 570-573.	3.2	131
324	Complete Sequence of p07-406, a 24,179-Base-Pair Plasmid Harboring the bla _{VIM-7} Metallo-Î²-Lactamase Gene in a Pseudomonas aeruginosa Isolate from the United States. Antimicrobial Agents and Chemotherapy, 2008, 52, 3099-3105.	3.2	23

#	Article	IF	Citations
325	Characterization of Vancomycin-Heteroresistant Staphylococcus aureus from the Metropolitan Area of Detroit, Michigan, over a 22-Year Period (1986 to 2007). Journal of Clinical Microbiology, 2008, 46, 2950-2954.	3.9	132
326	Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections. Journal of Antimicrobial Chemotherapy, 2008, 61, 1092-1098.	3.0	44
327	Rapid Emergence ofbla_{CTX-M}Among Enterobacteriaceae in U.S. Medical Centers: Molecular Evaluation from the MYSTIC Program (2007). Microbial Drug Resistance, 2008, 14, 211-216.	2.0	79
328	Increased Antimicrobial Susceptibility Profiles among Polymyxinâ€ResistantAcinetobacter baumanniiClinical Isolates. Clinical Infectious Diseases, 2008, 46, 1324-1326.	5.8	20
329	Antimicrobial Activity of DC-159a, a New Fluoroquinolone, against 1,149 Recently Collected Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2008, 52, 3763-3775.	3.2	16
330	Carbapenem-Resistant Isolates of Klebsiella pneumoniae in China and Detection of a Conjugative Plasmid (bla _{KPC-2} plus qnrB4) and a bla _{IMP-4} Gene. Antimicrobial Agents and Chemotherapy, 2008, 52, 798-799.	3.2	53
331	Antimicrobial Activity of Omiganan Pentahydrochloride against Contemporary Fungal Pathogens Responsible for Catheter-Associated Infections. Antimicrobial Agents and Chemotherapy, 2008, 52, 1187-1189.	3.2	43
332	Antimicrobial Activities of Ceftaroline and ME1036 Tested against Clinical Strains of Community-Acquired Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2008, 52, 1153-1155.	3.2	74
333	Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. Journal of Antimicrobial Chemotherapy, 2008, 63, 55-59.	3.0	139
334	Tigecycline Disk Diffusion Breakpoints of Acinetobacter spp.: a Clinical Point of View. Journal of Clinical Microbiology, 2007, 45, 2095-2096.	3.9	8
335	Characterization of an Integron Carrying bla IMP-1 and a New Aminoglycoside Resistance Gene, aac(6â€²)-31 , and Its Dissemination among Genetically Unrelated Clinical Isolates in a Brazilian Hospital. Antimicrobial Agents and Chemotherapy, 2007, 51, 2611-2614.	3.2	60
336	Activity of Dalbavancin Tested against Staphylococcus spp. and Î²-Hemolytic Streptococcus spp. Isolated from 52 Geographically Diverse Medical Centers in the United States. Journal of Clinical Microbiology, 2007, 45, 998-1004.	3.9	33
337	Factors Influencing Broth Microdilution Antimicrobial Susceptibility Test Results for Dalbavancin, a New Glycopeptide Agent. Journal of Clinical Microbiology, 2007, 45, 3151-3154.	3.9	42
338	Multicenter Studies of Tigecycline Disk Diffusion Susceptibility Results for Acinetobacter spp. Journal of Clinical Microbiology, 2007, 45, 227-230.	3.9	157
339	Prevalence and Significance of a Negative Extended-Spectrum Î²-Lactamase (ESBL) Confirmation Test Result after a Positive ESBL Screening Test Result for Isolates of Escherichia coli and Klebsiella pneumoniae : Results from the SENTRY Asia-Pacific Surveillance Program. Journal of Clinical Microbiology, 2007, 45, 1478-1482.	3.9	47
340	Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. Journal of Antimicrobial Chemotherapy, 2007, 61, 365-370.	3.0	87
341	Activity of Linezolid against 3,251 Strains of Uncommonly Isolated Gram-Positive Organisms: Report from the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy, 2007, 51, 1491-1493.	3.2	23
342	In71, anEnterobacter cloacae bla_{VIM-1}-Carrying Integron Related to In70.2 from ItalianPseudomonas aeruginosaIsolates: A SENTRY Antimicrobial Surveillance Program Report. Microbial Drug Resistance, 2007, 13, 130-134.	2.0	8

#	Article	IF	Citations
343	Molecular Characterization of Staphylococcus aureus Isolates from a 2005 Clinical Trial of Uncomplicated Skin and Skin Structure Infections. Antimicrobial Agents and Chemotherapy, 2007, 51, 3381-3384.	3.2	20
344	Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998â€“2004). Diagnostic Microbiology and Infectious Disease, 2007, 57, 7-13.	1.8	324
345	Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998â€“2004). Diagnostic Microbiology and Infectious Disease, 2007, 57, 109-116.	1.8	26
346	Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagnostic Microbiology and Infectious Disease, 2007, 57, 207-215.	1.8	47
347	Tigecycline (GAR-936) activity against Streptococcus gallolyticus (bovis) and viridans group streptococci. Diagnostic Microbiology and Infectious Disease, 2007, 57, 333-336.	1.8	23
348	Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype. Diagnostic Microbiology and Infectious Disease, 2007, 57, 341-344.	1.8	44
349	Bactericidal activity of cefepime and ceftriaxone tested against Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Disease, 2007, 57, 345-349.	1.8	1
350	Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002â€“2005). Diagnostic Microbiology and Infectious Disease, 2007, 57, 459-465.	1.8	61
351	Influence of polysorbate-80 when determining the tigecycline MIC by the reference method. Diagnostic Microbiology and Infectious Disease, 2007, 58, 145-146.	1.8	3
352	Oral Î²-lactams applied to uncomplicated infections of skin and skin structures. Diagnostic Microbiology and Infectious Disease, 2007, 57, S55-S65.	1.8	24
353	In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999â€“2004). Diagnostic Microbiology and Infectious Disease, 2007, 58, 27-32.	1.8	8
354	Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999â€“2004). Diagnostic Microbiology and Infectious Disease, 2007, 58, 19-26.	1.8	32
355	Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagnostic Microbiology and Infectious Disease, 2007, 58, 163-170.	1.8	280
356	Development of anidulafungin for disk diffusion susceptibility testing against Candida spp.. Diagnostic Microbiology and Infectious Disease, 2007, 58, 371-374.	1.8	5
357	Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Disease, 2007, 58, 1-7.	1.8	12
358	Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. Diagnostic Microbiology and Infectious Disease, 2007, 58, 9-17.	1.8	19
359	Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006). Diagnostic Microbiology and Infectious Disease, 2007, 59, 425-432.	1.8	36
360	ZyvoxÂ® Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagnostic Microbiology and Infectious Disease, 2007, 59, 199-209.	1.8	41

#	Article	IF	Citations
361	LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagnostic Microbiology and Infectious Disease, 2007, 59, 309-317.	1.8	100
362	Selection of a surrogate Î²-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem. Diagnostic Microbiology and Infectious Disease, 2007, 59, 467-472.	1.8	14
363	Oxazolidinone susceptibility patterns for 2005: International Report from the ZyvoxÂ® Annual Appraisal of Potency and Spectrum Study. International Journal of Antimicrobial Agents, 2007, 29, 295-301.	2.5	29
364	Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asiaâ€“Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003â€“2004). International Journal of Antimicrobial Agents, 2007, 30, 143-149.	2.5	63
365	Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections. International Journal of Antimicrobial Agents, 2007, 30, 514-520.	2.5	11
366	Global Emergence of Trimethoprim/Sulfamethoxazole Resistance inStenotrophomonas maltophiliaMediated by Acquisition ofsulGenes. Emerging Infectious Diseases, 2007, 13, 559-565.	4.3	210
367	Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infectious Diseases, 2007, 7, 29.	2.9	55
368	Occurrence and Characterization of Carbapenemase-Producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program (2000â€“2004). Microbial Drug Resistance, 2006, 12, 223-230.	2.0	133
369	Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004). Diagnostic Microbiology and Infectious Disease, 2006, 54, 249-257.	1.8	20
370	Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. International Journal of Antimicrobial Agents, 2006, 27, 557-560.	2.5	33
371	Occurrence of plasmidic AmpC type Î²-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004). International Journal of Antimicrobial Agents, 2006, 28, 578-581.	2.5	43
372	Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997â€“2004). Diagnostic Microbiology and Infectious Disease, 2006, 54, 13-21.	1.8	49
373	Contemporary antimicrobial activity of triple antibiotic ointment: a multiphased study of recent clinical isolates in the United States and Australia. Diagnostic Microbiology and Infectious Disease, 2006, 54, 63-71.	1.8	30
374	Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001â€“2004). Diagnostic Microbiology and Infectious Disease, 2006, 54, 157-164.	1.8	19
375	Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagnostic Microbiology and Infectious Disease, 2006, 54, 149-153.	1.8	55
376	Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections. Diagnostic Microbiology and Infectious Disease, 2006, 54, 83-87.	1.8	14
377	Outcomes evaluation of patients with ESBL- and nonâ€“ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. Diagnostic Microbiology and Infectious Disease, 2006, 54, 231-236.	1.8	55
378	Characterization of fluoroquinolone-resistant Î²-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: Report from the SENTRY Antimicrobial Surveillance Program (1997â€“2004). Diagnostic Microbiology and Infectious Disease, 2006, 55, 119-127.	1.8	60

#	Article	IF	Citations
379	Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999â€“2003). Diagnostic Microbiology and Infectious Disease, 2006, 56, 69-74.	1.8	73
380	Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA). Diagnostic Microbiology and Infectious Disease, 2006, 56, 57-62.	1.8	73
381	Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998â€“2003). Diagnostic Microbiology and Infectious Disease, 2006, 55, 157-164.	1.8	15
382	Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside. Diagnostic Microbiology and Infectious Disease, 2006, 55, 241-243.	1.8	30
383	Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998â€“2004). Diagnostic Microbiology and Infectious Disease, 2006, 56, 63-68.	1.8	33
384	Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients: Report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North America). Diagnostic Microbiology and Infectious Disease, 2006, 56, 75-82.	1.8	33
385	Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model. Diagnostic Microbiology and Infectious Disease, 2006, 56, 379-386.	1.8	10
386	Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: Report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. Diagnostic Microbiology and Infectious Disease, 2006, 56, 427-436.	1.8	88
387	Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: Report from the MYSTIC Program (1999â€“2005). Diagnostic Microbiology and Infectious Disease, 2006, 56, 367-372.	1.8	124
388	Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: time for local guidelines?. Memorias Do Instituto Oswaldo Cruz, 2006, 101, 741-748.	1.6	70
389	Comparison of Dalbavancin MIC Values Determined by Etest (AB BIODISK) and Reference Dilution Methods Using Gram-Positive Organisms. Journal of Clinical Microbiology, 2006, 44, 2988-2990.	3.9	25
390	Activity of Retapamulin (SB-275833), a Novel Pleuromutilin, against Selected Resistant Gram-Positive Cocci. Antimicrobial Agents and Chemotherapy, 2006, 50, 2583-2586.	3.2	112
391	The Activity of Daptomycin Against Wild-Type Staphylococcus aureus and Strains with Reduced Susceptibility to Vancomycin. Clinical Infectious Diseases, 2006, 43, 798-799.	5.8	35
392	Oxazolidinone susceptibility patterns in 2004: report from the ZyvoxÂ® Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. Journal of Antimicrobial Chemotherapy, 2006, 57, 279-287.	3.0	71
393	Accuracy of Three Automated Systems (MicroScan WalkAway, VITEK, and VITEK 2) for Susceptibility Testing of Pseudomonas aeruginosa against Five Broad-Spectrum Beta-Lactam Agents. Journal of Clinical Microbiology, 2006, 44, 1101-1104.	3.9	58
394	Carbapenem Susceptibility Discords among Acinetobacter Isolates. Clinical Infectious Diseases, 2006, 42, 158-158.	5.8	22
395	Daptomycin Bactericidal Activity and Correlation between Disk and Broth Microdilution Method Results in Testing of Staphylococcus aureus Strains with Decreased Susceptibility to Vancomycin. Antimicrobial Agents and Chemotherapy, 2006, 50, 2330-2336.	3.2	77
396	Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. Journal of Antimicrobial Chemotherapy, 2006, 58, 481-483.	3.0	56

#	Article	IF	Citations
397	Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003â€“2004). Journal of Antimicrobial Chemotherapy, 2006, 57, 914-923.	3.0	25
398	International Surveillance of Candida spp. and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2003). Journal of Clinical Microbiology, 2006, 44, 1782-1787.	3.9	146
399	Selection of a Surrogate Agent (Vancomycin or Teicoplanin) for Initial Susceptibility Testing of Dalbavancin: Results from an International Antimicrobial Surveillance Program. Journal of Clinical Microbiology, 2006, 44, 2622-2625.	3.9	18
400	Changing Antimicrobial Susceptibility Patterns among Streptococcus pneumoniae and Haemophilus influenzae from Brazil: Report from the SENTRY Antimicrobial Surveillance Program (1998â€“2004). Microbial Drug Resistance, 2006, 12, 91-98.	2.0	9
401	Microbiological Features of Vancomycin in the 21st Century: Minimum Inhibitory Concentration Creep, Bactericidal/Static Activity, and Applied Breakpoints to Predict Clinical Outcomes or Detect Resistant Strains. Clinical Infectious Diseases, 2006, 42, S13-S24.	5.8	218
402	Activity of DX-619 Compared to Other Agents against Viridans Group Streptococci, Streptococcus bovis , and Cardiobacterium hominis. Antimicrobial Agents and Chemotherapy, 2006, 50, 4191-4194.	3.2	1
403	Comment on: Linezolid resistance in coagulase-negative staphylococci2. Journal of Antimicrobial Chemotherapy, 2006, 58, 899-900.	3.0	4
404	Multicenter Evaluation of the Etest and Disk Diffusion Methods for Differentiating Daptomycin-Susceptible from Non-Daptomycin-Susceptible Staphylococcus aureus Isolates. Journal of Clinical Microbiology, 2006, 44, 3098-3104.	3.9	30
405	Contemporary Prevalence of BRO Î²-Lactamases in Moraxella catarrhalis : Report from the SENTRY Antimicrobial Surveillance Program (North America, 1997 to 2004). Journal of Clinical Microbiology, 2006, 44, 3775-3777.	3.9	21
406	Comparison of Censored Regression and Standard Regression Analyses for Modeling Relationships between Antimicrobial Susceptibility and Patient- and Institution-Specific Variables. Antimicrobial Agents and Chemotherapy, 2006, 50, 62-67.	3.2	4
407	Performance Accuracy of Antibacterial and Antifungal Susceptibility Test Methods: Report From the College of American Pathologists Microbiology Surveys Program (2001â€“2003). Archives of Pathology and Laboratory Medicine, 2006, 130, 767-778.	2.5	53
408	In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America. Brazilian Journal of Infectious Diseases, 2005, 9, 348-356.	0.6	25
409	IntegratingEscherichia coliAntimicrobial Susceptibility Data from Multiple Surveillance Programs. Emerging Infectious Diseases, 2005, 11, 873-882.	4.3	52
410	Antimicrobial susceptibility patterns of unusual nonfermentative gram-negative bacilli isolated from Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2002). Memorias Do Instituto Oswaldo Cruz, 2005, 100, 571-577.	1.6	37
411	Emerging Metalloâ€Î²â€Lactamaseâ€“Mediated Resistances: A Summary Report from the Worldwide SENTRY Antimicrobial Surveillance Program. Clinical Infectious Diseases, 2005, 41, S276-S278.	5.8	72
412	Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis. Journal of Antimicrobial Chemotherapy, 2005, 55, 574-578.	3.0	32
413	Antimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains. Antimicrobial Agents and Chemotherapy, 2005, 49, 3501-3512.	3.2	137
414	Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. Journal of Antimicrobial Chemotherapy, 2005, 56, 1047-1052.	3.0	33

#	Article	IF	Citations
415	Italian metallo-Î²-lactamases: a national problem? Report from the SENTRY Antimicrobial Surveillance Programme. Journal of Antimicrobial Chemotherapy, 2005, 55, 61-70.	3.0	83
416	Quality Control Guidelines for Susceptibility Testing of Retapamulin (SB-275833) by Reference and Standardized Methods. Journal of Clinical Microbiology, 2005, 43, 6212-6213.	3.9	11
417	Comparative Antimicrobial Characterization of LBM415 (NVP PDF-713), a New Peptide Deformylase Inhibitor of Clinical Importance. Antimicrobial Agents and Chemotherapy, 2005, 49, 1468-1476.	3.2	52
418	Application of an In Vitro Infection Model and Simulation for Reevaluation of Fluoroquinolone Breakpoints for Salmonella enterica Serotype Typhi. Antimicrobial Agents and Chemotherapy, 2005, 49, 1775-1781.	3.2	48
419	Evolution and dissemination of extended-spectrum Î²-lactamase-producing Klebsiella pneumoniae: Epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997â€“2003). Diagnostic Microbiology and Infectious Disease, 2005, 51, 1-7.	1.8	40
420	Evaluation of alternative disk diffusion methods for detecting mecA-mediated oxacillin resistance in an international collection of staphylococci: Validation report from the SENTRY antimicrobial surveillance program. Diagnostic Microbiology and Infectious Disease, 2005, 51, 57-62.	1.8	44
421	Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diagnostic Microbiology and Infectious Disease, 2005, 51, 31-37.	1.8	53
422	Comparative activity of oral and parenteral cephalosporins tested against multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1997â€“2003). Diagnostic Microbiology and Infectious Disease, 2005, 51, 147-150.	1.8	22
423	Reproducibility assessment of tigecycline MIC results by broth microdilution methods using commercially prepared dry-form panels. Diagnostic Microbiology and Infectious Disease, 2005, 52, 67-69.	1.8	0
424	Reevaluation of the cefepime minimal inhibitory concentrations and disk diffusion test zone diameter relationship for a worldwide collection of Enterobacteriaceae enriched for extended-spectrum Î²-lactamaseâ€“producing organisms. Diagnostic Microbiology and Infectious Disease, 2005, 52, 95-99.	1.8	3
425	Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various Î²-lactamase resistance mechanisms. Diagnostic Microbiology and Infectious Disease, 2005, 52, 71-74.	1.8	117
426	Trends in linezolid susceptibility patterns in 2002: Report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagnostic Microbiology and Infectious Disease, 2005, 52, 53-58.	1.8	43
427	Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: Results from the SENTRY Antimicrobial Surveillance Program (1998â€“2003). Diagnostic Microbiology and Infectious Disease, 2005, 52, 265-273.	1.8	55
428	Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 Î²-lactams: adjustments of breakpoints for strains producing extended spectrum Î²-lactamases. Diagnostic Microbiology and Infectious Disease, 2005, 52, 235-246.	1.8	26
429	Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagnostic Microbiology and Infectious Disease, 2005, 53, 307-310.	1.8	69
430	Regional variation in the prevalence of extended-spectrum Î²-lactamaseâ€“producing clinical isolates in the Asia-Pacific region (SENTRY 1998â€“2002). Diagnostic Microbiology and Infectious Disease, 2005, 52, 323-329.	1.8	136
431	Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagnostic Microbiology and Infectious Disease, 2005, 52, 203-208.	1.8	94
432	Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000â€“2004). Diagnostic Microbiology and Infectious Disease, 2005, 52, 195-201.	1.8	55

#	Article	IF	Citations
433	Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagnostic Microbiology and Infectious Disease, 2005, 52, 187-193.	1.8	78
434	Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagnostic Microbiology and Infectious Disease, 2005, 52, 181-186.	1.8	106
435	Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagnostic Microbiology and Infectious Disease, 2005, 52, 209-213.	1.8	63
436	Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003). Diagnostic Microbiology and Infectious Disease, 2005, 53, 329-332.	1.8	26
437	An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997â€“2004. Diagnostic Microbiology and Infectious Disease, 2005, 53, 247-256.	1.8	36
438	Cefdinir activity against contemporary North American isolates from community-acquired urinary tract infections. International Journal of Antimicrobial Agents, 2005, 25, 89-92.	2.5	10
439	Dissemination and diversity of metallo-Î²-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program. International Journal of Antimicrobial Agents, 2005, 25, 57-61.	2.5	93
440	Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. International Journal of Antimicrobial Agents, 2005, 25, 95-109.	2.5	155
441	Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002â€“2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents. International Journal of Antimicrobial Agents, 2005, 25, 282-289.	2.5	24
442	Reproducibility of daptomycin MIC results using dry-form commercial trays with appropriate supplemental calcium content. International Journal of Antimicrobial Agents, 2005, 25, 274-275.	2.5	3
443	Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp.. International Journal of Antimicrobial Agents, 2005, 25, 380-384.	2.5	34
444	Trends in linezolid susceptibility patterns: report from the 2002â€“2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. International Journal of Antimicrobial Agents, 2005, 26, 13-21.	2.5	55
445	Public Health Consequences of Macrolide Use in Food Animals: A Deterministic Risk Assessment. Journal of Food Protection, 2004, 67, 980-992.	1.7	72
446	SENTRY antimicrobial surveillance program report: latin american and brazilian results for 1997 through 2001. Brazilian Journal of Infectious Diseases, 2004, 8, 25-79.	0.6	101
447	Genotypic Characterization of Carbapenem-NonsusceptibleAcinetobacterspp. Isolated in Latin America. Microbial Drug Resistance, 2004, 10, 286-291.	2.0	11
448	Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. Journal of Antimicrobial Chemotherapy, 2004, 53, 669-674.	3.0	130
449	Initial results from a longitudinal international surveillance programme for anidulafungin (2003). Journal of Antimicrobial Chemotherapy, 2004, 54, 1051-1056.	3.0	50
450	Emergence of Two Klebsiella pneumoniae Isolates Harboring Plasmid-Mediated CTX-M-15 Î²-Lactamase in Taiwan. Antimicrobial Agents and Chemotherapy, 2004, 48, 362-363.	3.2	17

#	Article	IF	Citations
451	Activities of Doripenem (S-4661) against Drug-Resistant Clinical Pathogens. Antimicrobial Agents and Chemotherapy, 2004, 48, 3136-3140.	3.2	110
452	Pseudomonas aeruginosa strains harbouring an unusual blaVIM-4 gene cassette isolated from hospitalized children in Poland (1998-2001). Journal of Antimicrobial Chemotherapy, 2004, 53, 451-456.	3.0	62
453	bla VIM-7 , an Evolutionarily Distinct Metallo-Î²-Lactamase Gene in a Pseudomonas aeruginosa Isolate from the United States. Antimicrobial Agents and Chemotherapy, 2004, 48, 329-332.	3.2	129
454	First Isolation of bla VIM-2 in Latin America: Report from the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy, 2004, 48, 1433-1434.	3.2	45
455	In Vitro Activities of the Novel Cephalosporin LB 11058 against Multidrug-Resistant Staphylococci and Streptococci. Antimicrobial Agents and Chemotherapy, 2004, 48, 53-62.	3.2	81
456	Quality Control Guidelines for MIC Susceptibility Testing of Omiganan Pentahydrochloride (MBI 226), a Novel Antimicrobial Peptide. Journal of Clinical Microbiology, 2004, 42, 1386-1387.	3.9	15
457	Omiganan Pentahydrochloride (MBI 226), a Topical 12-Amino-Acid Cationic Peptide: Spectrum of Antimicrobial Activity and Measurements of Bactericidal Activity. Antimicrobial Agents and Chemotherapy, 2004, 48, 3112-3118.	3.2	115
458	Are Enterococcus faecalis Strains with vat (E) in Poultry a Reservoir for Human Streptogramin Resistance? vat (E) Occurrence in Human Enterococcal Bloodstream Infections in North America (SENTRY Antimicrobial Surveillance Program, 2002). Antimicrobial Agents and Chemotherapy, 2004, 48, 360-361.	3.2	5
459	Molecular Characterization of a Î²-Lactamase Gene, bla GIM-1 , Encoding a New Subclass of Metallo-Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2004, 48, 4654-4661.	3.2	236
460	Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). Journal of Antimicrobial Chemotherapy, 2004, 53, 290-296.	3.0	95
461	Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates. Journal of Antimicrobial Chemotherapy, 2004, 53, 804-807.	3.0	24
462	Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. Journal of Antimicrobial Chemotherapy, 2004, 54, 144-154.	3.0	110
463	Antimicrobial Susceptibility and Epidemiology of a Worldwide Collection of Chryseobacterium spp.: Report from the SENTRY Antimicrobial Surveillance Program (1997-2001). Journal of Clinical Microbiology, 2004, 42, 445-448.	3.9	230
464	Integron Carrying a Novel Metallo-Î²-Lactamase Gene, bla IMP-16 , and a Fused Form of Aminoglycoside-Resistant Gene aac(6â€²)-30/aac(6â€²)-Ibâ€² : Report from the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy, 2004, 48, 4693-4702.	3.2	86
465	Surveillance in Taiwan Using Molecular Epidemiology for Extended-Spectrum Beta-Lactamase-ProducingKlebsiella pneumoniae. Infection Control and Hospital Epidemiology, 2004, 25, 812-818.	1.8	10
466	Preliminary susceptibility testing guidelines for AZD2563, a long-acting oxazolidinone. International Journal of Antimicrobial Agents, 2004, 23, 6-10.	2.5	7
467	Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres. International Journal of Antimicrobial Agents, 2004, 23, 52-59.	2.5	34
468	Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. International Journal of Antimicrobial Agents, 2004, 23, 197-199.	2.5	23

#	Article	IF	Citations
469	Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). International Journal of Antimicrobial Agents, 2004, 24, 111-118.	2.5	162
470	Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections. International Journal of Antimicrobial Agents, 2004, 24, 567-571.	2.5	29
471	Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program. International Journal of Infectious Diseases, 2004, 8, 284-291.	3.3	66
472	Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagnostic Microbiology and Infectious Disease, 2004, 48, 137-143.	1.8	136
473	A pragmatic approach to identify extended-spectrum Î²-lactamase-producing klebsiella pneumoniae in taiwan: in vitro activity of newer and established antimicrobial agents. Diagnostic Microbiology and Infectious Disease, 2004, 48, 277-282.	1.8	6
474	Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent gram-positive clinical isolates. Diagnostic Microbiology and Infectious Disease, 2004, 49, 63-65.	1.8	28
475	Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: Report of year five (2003). Diagnostic Microbiology and Infectious Disease, 2004, 49, 273-281.	1.8	25
476	In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagnostic Microbiology and Infectious Disease, 2004, 49, 201-209.	1.8	74
477	Molecular epidemiology of selected multidrug-resistant bacteria: A global report from the SENTRY Antimicrobial Surveillance Program. Diagnostic Microbiology and Infectious Disease, 2004, 49, 231-236.	1.8	43
478	Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999â€“2003). Diagnostic Microbiology and Infectious Disease, 2004, 49, 211-216.	1.8	32
479	Evaluation of the contemporary occurrence rates of metallo-Î²-lactamases in multidrug-resistant Gram-negative bacilli in Japan: Report from the SENTRY Antimicrobial Surveillance Program (1998â€“2002). Diagnostic Microbiology and Infectious Disease, 2004, 49, 289-294.	1.8	27
480	Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. Diagnostic Microbiology and Infectious Disease, 2004, 50, 73-75.	1.8	44
481	Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: A sample of North American isolates. Diagnostic Microbiology and Infectious Disease, 2004, 49, 283-287.	1.8	11
482	Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997â€“2002). Diagnostic Microbiology and Infectious Disease, 2004, 50, 59-69.	1.8	326
483	Antimicrobial activity of daptomycin against multidrug-resistant gram-positive strains collected worldwide. Diagnostic Microbiology and Infectious Disease, 2004, 50, 201-204.	1.8	65
484	Disk diffusion quality control guidelines for NVP-PDF 713: a novel peptide deformylase inhibitor. Diagnostic Microbiology and Infectious Disease, 2004, 48, 55-57.	1.8	6
485	Sustained activity and spectrum of selected extended-spectrum Î²-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997â€“2000). International Journal of Antimicrobial Agents, 2003, 21, 1-7.	2.5	58
486	Salmonella bloodstream infections: report from the SENTRY Antimicrobial Surveillance Program (1997â€“2001). International Journal of Antimicrobial Agents, 2003, 22, 395-405.	2.5	21

#	Article	IF	Citations
487	Quality control guidelines for MIC susceptibility testing of NVP PDF-713: a novel peptide deformylase inhibitor. International Journal of Antimicrobial Agents, 2003, 22, 84-86.	2.5	8
488	Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18â€˜569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997â€“2001). International Journal of Antimicrobial Agents, 2003, 22, 551-556.	2.5	100
489	Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). Diagnostic Microbiology and Infectious Disease, 2003, 45, 295-301.	1.8	94
490	Determination of disk diffusion and MIC quality control parameters for AZD2563, a novel long-acting oxazolidinone. Diagnostic Microbiology and Infectious Disease, 2003, 45, 73-76.	1.8	2
491	Emergence of an IMP-like metallo-enzyme in an Acinetobacter baumannii clinical strain from a Brazilian teaching hospital. Diagnostic Microbiology and Infectious Disease, 2003, 45, 77-79.	1.8	62
492	Confirmation of extended-spectrum Î²-lactamase-producing Serratia marcescens: preliminary report from Taiwan. Diagnostic Microbiology and Infectious Disease, 2003, 45, 221-224.	1.8	26
493	Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagnostic Microbiology and Infectious Disease, 2003, 45, 279-285.	1.8	122
494	Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.8	156
495	Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999â€“2001). Diagnostic Microbiology and Infectious Disease, 2003, 45, 273-278.	1.8	27
496	Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY Antimicrobial Surveillance Program (1997â€“2000). Diagnostic Microbiology and Infectious Disease, 2003, 46, 63-68.	1.8	60
497	Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2001): report from the SENTRY Antimicrobial Surveillance Program. Diagnostic Microbiology and Infectious Disease, 2003, 46, 77-80.	1.8	31
498	Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance program. Diagnostic Microbiology and Infectious Disease, 2003, 46, 55-61.	1.8	45
499	Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001). Diagnostic Microbiology and Infectious Disease, 2003, 47, 361-364.	1.8	49
500	Antimicrobial susceptibility profile among Î²-haemolytic Streptococcus spp. collected in the SENTRY antimicrobial surveillance programâ€”North America, 2001. Diagnostic Microbiology and Infectious Disease, 2003, 46, 291-294.	1.8	33
501	Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY antimicrobial surveillance program. Diagnostic Microbiology and Infectious Disease, 2003, 46, 285-289.	1.8	66
502	Susceptibility trends of haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program. Diagnostic Microbiology and Infectious Disease, 2003, 47, 373-376.	1.8	56
503	Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America. Diagnostic Microbiology and Infectious Disease, 2003, 47, 365-372.	1.8	54
504	Comparative activity and spectrum of broad-spectrum Î²-lactams (cefepime, ceftazidime, ceftriaxone,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf antimicrobial surveillance program (North America: 2001-2002). Diagnostic Microbiology and Infectious Disease, 2003, 47, 435-440.	1.8	40

#	Article	IF	Citations
505	Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and Î²-lactams tested against gram-negative bacilli. Diagnostic Microbiology and Infectious Disease, 2003, 47, 547-550.	1.8	33
506	Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002). Diagnostic Microbiology and Infectious Disease, 2003, 47, 515-525.	1.8	24
507	Worldwide Antimicrobial Susceptibility Patterns and Pharmacodynamic Comparisons of Gatifloxacin and Levofloxacin against Streptococcus pneumoniae : Report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrobial Agents and Chemotherapy, 2003, 47, 292-296.	3.2	58
508	Molecular Epidemiology of Macrolide Resistance in Neonatal Bloodstream Isolates of Group B Streptococci. Journal of Clinical Microbiology, 2003, 41, 2659-2661.	3.9	42
509	Relationships between Patient- and Institution-Specific Variables and Decreased Antimicrobial Susceptibility of Gram-Negative Pathogens. Clinical Infectious Diseases, 2003, 37, 344-350.	5.8	12
510	Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997-2001). Journal of Antimicrobial Chemotherapy, 2003, 52, 140-141.	3.0	89
511	Genetic characterization of a novel metallo-Â-lactamase gene, blaIMP-13, harboured by a novel Tn5051-type transposon disseminating carbapenemase genes in Europe: report from the SENTRY worldwide antimicrobial surveillance programme. Journal of Antimicrobial Chemotherapy, 2003, 52, 583-590.	3.0	81
512	Quinupristin-Dalfopristin Resistance in Streptococcus pneumoniae : Novel L22 Ribosomal Protein Mutation in Two Clinical Isolates from the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy, 2003, 47, 2696-2698.	3.2	27
513	Molecular and Biochemical Characterization of OXA-45, an Extended-Spectrum Class 2dâ€² Î²-Lactamase in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2003, 47, 2859-2863.	3.2	47
514	CANCER Resistance Surveillance Program: Initial Results from Hematologyâ€“Oncology Centers in North America. Annals of Pharmacotherapy, 2003, 37, 47-56.	1.9	31
515	Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor. Journal of Antimicrobial Chemotherapy, 2003, 51, 157-161.	3.0	20
516	Linezolid Resistance since 2001: SENTRY Antimicrobial Surveillance Program. Annals of Pharmacotherapy, 2003, 37, 769-774.	1.9	151
517	Evolution of an integron carrying blaVIM-2 in Eastern Europe: report from the SENTRY Antimicrobial Surveillance Program. Journal of Antimicrobial Chemotherapy, 2003, 52, 116-119.	3.0	58
518	Biochemical Characterization of the Acquired Metallo-Î²-Lactamase SPM-1 from Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2003, 47, 582-587.	3.2	66
519	Initial Quality Control Evaluations for Susceptibility Testing of Dalbavancin (BI397), an Investigational Glycopeptide with Potent Gram-Positive Activity. Journal of Clinical Microbiology, 2003, 41, 2795-2796.	3.9	29
520	Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific. Journal of Antimicrobial Chemotherapy, 2003, 51, 339-345.	3.0	23
521	Global Epidemiology of Antimicrobial Resistance among Community-Acquired and Nosocomial Pathogens: A Five-Year Summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Seminars in Respiratory and Critical Care Medicine, 2003, 24, 121-134.	2.1	144
522	In vitro evaluation of AZD2563, a new oxazolidinone, tested against beta-haemolytic and viridans group streptococci. Journal of Antimicrobial Chemotherapy, 2002, 49, 1019-1021.	3.0	5

#	Article	IF	Citations
523	In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. Journal of Antimicrobial Chemotherapy, 2002, 50, 915-932.	3.0	117
524	Tiamulin Activity against Fastidious and Nonfastidious Veterinary and Human Bacterial Isolates: Initial Development of In Vitro Susceptibility Test Methods. Journal of Clinical Microbiology, 2002, 40, 461-465.	3.9	23
525	BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10 000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000). Journal of Antimicrobial Chemotherapy, 2002, 49, 851-855.	3.0	13
526	In Vitro Evaluation of AZD2563, a Novel Oxazolidinone, against 603 Recent Staphylococcal Isolates. Antimicrobial Agents and Chemotherapy, 2002, 46, 2662-2664.	3.2	11
527	First Description of Klebsiella pneumoniae Harboring CTX-M Î²-Lactamases (CTX-M-14 and CTX-M-3) in Taiwan. Antimicrobial Agents and Chemotherapy, 2002, 46, 1098-1100.	3.2	44
528	Molecular characterization of SPM-1, a novel metallo-beta-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. Journal of Antimicrobial Chemotherapy, 2002, 50, 673-679.	3.0	277
529	Pharmacodynamics in the Evaluation of Drug Regimens. Annals of Pharmacotherapy, 2002, 36, 530-532.	1.9	5
530	Antimicrobial susceptibility of inducible AmpC Î²-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997â€“2000. International Journal of Antimicrobial Agents, 2002, 19, 383-388.	2.5	18
531	Pathogen occurrence and antimicrobial resistance trends among urinary tract infection isolates in the Asia-Western Pacific Region: report from the SENTRY Antimicrobial Surveillance Program, 1998â€“1999. International Journal of Antimicrobial Agents, 2002, 20, 10-17.	2.5	46
532	Re-evaluations of disk diffusion quality control ranges for 11 drugs: report from the QC working group of the national committee for clinical laboratory standards. International Journal of Antimicrobial Agents, 2002, 20, 289-292.	2.5	1
533	A comparison of the antimicrobial activity of meropenem and selected broad-spectrum antimicrobials tested against multi-drug resistant Gram-negative bacilli including bacteraemic Salmonella spp.:. International Journal of Antimicrobial Agents, 2002, 20, 426-431.	2.5	31
534	In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual gram-positive species. Diagnostic Microbiology and Infectious Disease, 2002, 42, 119-122.	1.8	17
535	In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum. Diagnostic Microbiology and Infectious Disease, 2002, 42, 145-147.	1.8	35
536	Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagnostic Microbiology and Infectious Disease, 2002, 42, 137-139.	1.8	92
537	A multicenter evaluation of linezolid antimicrobial activity in North America. Diagnostic Microbiology and Infectious Disease, 2002, 43, 75-83.	1.8	70
538	Ciprofloxacin as broad-spectrum empiric therapyâ€”are fluoroquinolones still viable monotherapeutic agents compared with Î²-lactams: Data from the MYSTIC Program (US)?. Diagnostic Microbiology and Infectious Disease, 2002, 42, 213-215.	1.8	14
539	Prevalence of extended spectrum Î²-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998â€“99). Diagnostic Microbiology and Infectious Disease, 2002, 42, 193-198.	1.8	111
540	Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections. Diagnostic Microbiology and Infectious Disease, 2002, 43, 49-60.	1.8	35

#	Article	IF	Citations
541	Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998â€“2000. Diagnostic Microbiology and Infectious Disease, 2002, 43, 65-73.	1.8	67
542	Antimicrobial susceptibility patterns of Î²-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997â€“2000). Diagnostic Microbiology and Infectious Disease, 2002, 43, 157-162.	1.8	70
543	Evaluation of in vitro susceptibility testing criteria for gemifloxacin when tested against Haemophilus influenzae strains with reduced susceptibility to ciprofloxacin and ofloxacin. Diagnostic Microbiology and Infectious Disease, 2002, 43, 323-326.	1.8	2
544	Geographic variations in activity of broad-spectrum Î²-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997â€“2000). Diagnostic Microbiology and Infectious Disease, 2002, 43, 239-243.	1.8	74
545	In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998â€“1999). Diagnostic Microbiology and Infectious Disease, 2002, 43, 315-318.	1.8	3
546	Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagnostic Microbiology and Infectious Disease, 2002, 43, 303-309.	1.8	35
547	Microbiology of newer fluoroquinolones: focus on respiratory pathogens. Diagnostic Microbiology and Infectious Disease, 2002, 44, 213-220.	1.8	23
548	Antimicrobial activity of broad-spectrum agents tested against gram-negative bacilli resistant to ceftazidime: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Diagnostic Microbiology and Infectious Disease, 2002, 44, 379-382.	1.8	17
549	Gatifloxacin Phase IV surveillance trial (TeqCES Study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections. Diagnostic Microbiology and Infectious Disease, 2002, 44, 77-84.	1.8	15
550	Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Disease, 2002, 44, 93-100.	1.8	19
551	Evaluation of the in vitro activity of six broad-spectrum Î²-lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories. Diagnostic Microbiology and Infectious Disease, 2002, 44, 367-377.	1.8	59
552	Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns. Diagnostic Microbiology and Infectious Disease, 2002, 44, 281-288.	1.8	64
553	Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers. Diagnostic Microbiology and Infectious Disease, 2002, 44, 273-280.	1.8	82
554	Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997â€“2000). Diagnostic Microbiology and Infectious Disease, 2002, 44, 289-299.	1.8	92
555	Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagnostic Microbiology and Infectious Disease, 2002, 44, 301-311.	1.8	62
556	Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. Journal of Antimicrobial Chemotherapy, 2002, 49, 445-453.	3.0	28
557	Molecular Typing and Antimicrobial Susceptibility of Vancomycin-ResistantEnterococcus faeciumin Brazil. Infection Control and Hospital Epidemiology, 2002, 23, 19-22.	1.8	20
558	Cefepime MIC as a Predictor of the Extended-Spectrum Î²-Lactamase Type inKlebsiella pneumoniae,Taiwan. Emerging Infectious Diseases, 2002, 8, 522-524.	4.3	36

#	Article	IF	Citations
559	Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the ZyvoxÂ® Antimicrobial Potency Study in Latin America (LA-ZAPS). Brazilian Journal of Infectious Diseases, 2002, 6, 100-9.	0.6	15
560	Comparative antimicrobial activity of ABT-773, a novel ketolide, tested against drug-resistant Gram-positive cocci and Haemophilus influenzae. International Journal of Antimicrobial Agents, 2001, 17, 451-455.	2.5	5
561	Characterization of extended spectrum Î²-lactamase-producing Klebsiella pneumoniae from Beijing, China. International Journal of Antimicrobial Agents, 2001, 18, 185-188.	2.5	11
562	Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment. American Journal of Medicine, 2001, 111, 4-12.	1.5	71
563	In vitro activity of linezolid (U-100766) against Haemophilus influenzae measured by three different susceptibility testing methods. Diagnostic Microbiology and Infectious Disease, 2001, 39, 49-53.	1.8	8
564	Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f Î²-lactamase (SME-1) in the United States: results from the MYSTIC Programme. Diagnostic Microbiology and Infectious Disease, 2001, 39, 125-127.	1.8	37
565	Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: Iâ€"results from the SENTRY Antimicrobial Surveillance Program (North) Tj ETQq1 1 0.784314 rgBT /Overlo	1.8	13
566	Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States. Diagnostic Microbiology and Infectious Disease, 2001, 39, 245-250.	1.8	24
567	Accuracy of broth microdilution and E test methods for detecting chloramphenicol acetyl transferase mediated resistance in Streptococcus pneumoniae: Geographic variations in the prevalence of resistance in The SENTRY Antimicrobial Surveillance Program (1999). Diagnostic Microbiology and Infectious Disease, 2001, 39, 267-269.	1.8	5
568	Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997â€"99). Diagnostic Microbiology and Infectious Disease, 2001, 39, 237-243.	1.8	22
569	Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagnostic Microbiology and Infectious Disease, 2001, 39, 257-260.	1.8	59
570	Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the ZyvoxÂ® Antimicrobial Potency Study (ZAPS) in the United States. Diagnostic Microbiology and Infectious Disease, 2001, 40, 59-66.	1.8	70
571	Validation of cefditoren MIC quality control ranges by a multi-laboratory study (2001). Diagnostic Microbiology and Infectious Disease, 2001, 40, 71-73.	1.8	1
572	Proposed quality control guidelines for National Committee for Clinical Laboratory Standards Susceptibility Tests using the veterinary antimicrobial agent tiamulin. Diagnostic Microbiology and Infectious Disease, 2001, 40, 67-70.	1.8	6
573	Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.. Diagnostic Microbiology and Infectious Disease, 2001, 40, 45-49.	1.8	18
574	In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum Î²-lactamases. Diagnostic Microbiology and Infectious Disease, 2001, 40, 173-177.	1.8	97
575	Cefditoren in vitro activity and spectrum: a review of international studies using reference methods. Diagnostic Microbiology and Infectious Disease, 2001, 41, 1-14.	1.8	24
576	Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): More alike than different!. Diagnostic Microbiology and Infectious Disease, 2001, 41, 161-163.	1.8	30

#	Article	IF	Citations
577	MYSTIC preface. Diagnostic Microbiology and Infectious Disease, 2001, 41, 169.	1.8	1
578	Determining the value of antimicrobial surveillance programs. Diagnostic Microbiology and Infectious Disease, 2001, 41, 171-175.	1.8	577
579	Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). Diagnostic Microbiology and Infectious Disease, 2001, 41, 177-182.	1.8	54
580	MYSTIC: closing summary. Diagnostic Microbiology and Infectious Disease, 2001, 41, 197-198.	1.8	2
581	Oxazolidinone antibiotics. Lancet, The, 2001, 358, 1975-1982.	13.7	356
582	Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY antimicrobial surveillance program. Brazilian Journal of Infectious Diseases, 2001, 5, 200-14.	0.6	97
583	Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the Global SMART (GSMART) surveillance study. Brazilian Journal of Infectious Diseases, 2001, 5, 21-31.	0.6	17
584	Resistance Patterns Among Nosocomial Pathogens. Chest, 2001, 119, 397S-404S.	0.8	285
585	Activities of BMS 284756 (T-3811) against Haemophilus influenzae , Moraxella catarrhalis , and Streptococcus pneumoniae Isolates from SENTRY Antimicrobial Surveillance Program Medical Centers in Latin America (1999). Antimicrobial Agents and Chemotherapy, 2001, 45, 1463-1466.	3.2	22
586	Comparison of the Vitek Gram-Positive Susceptibility 106 Card and the MRSA-Screen Latex Agglutination Test for Determining Oxacillin Resistance in Clinical Bloodstream Isolates of Staphylococcus aureus. Journal of Clinical Microbiology, 2001, 39, 53-56.	3.9	50
587	Antimicrobial Susceptibility Testing of Clinical Isolates of Bordetella pertussis from Northern California: Report from the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy, 2001, 45, 3599-3600.	3.2	26
588	Sensibilidade a antimicrobianos de bactÃ©rias isoladas do trato respiratÃ³rio de pacientes com infecÃ§Ãµes respiratÃ³rias adquiridas na comunidade: resultados brasileiros do Programa SENTRY de VigilÂ¢ncia de ResistÃªncia a Antimicrobianos dos anos de 1997 e 1998. Jornal De Pneumologia, 2001, 27, 25-34.	0.1	5
589	Perfil de sensibilidade a antimicrobianos de bactÃ©rias isoladas do trato respiratÃ³rio baixo de pacientes com pneumonia internados em hospitais brasileiros: resultados do Programa SENTRY, 1997 e 1998. Jornal De Pneumologia, 2001, 27, 59-67.	0.1	9
590	Method Preferences and Test Accuracy of Antimicrobial Susceptibility Testing. Archives of Pathology and Laboratory Medicine, 2001, 125, 1285-1289.	2.5	31
591	Group B streptococci causing neonatal bloodstream infection: Antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere. American Journal of Obstetrics and Gynecology, 2000, 183, 859-862.	1.3	103
592	Genetic Relatedness of Multidrug-Resistant, Methicillin (Oxacillin)-ResistantStaphylococcus aureusBloodstream Isolates from SENTRY Antimicrobial Resistance Surveillance Centers Worldwide, 1998. Microbial Drug Resistance, 2000, 6, 213-221.	2.0	55
593	Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY Antimicrobial Surveillance Program (1998). Journal of Antimicrobial Chemotherapy, 2000, 45, 295-303.	3.0	134
594	In Vitro Activity of Newer Fluoroquinolones for Respiratory Tract Infections and Emerging Patterns of Antimicrobial Resistance: Data from the SENTRY Antimicrobial Surveillance Program. Clinical Infectious Diseases, 2000, 31, S16-S23.	5.8	81

#	Article	IF	Citations
595	Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility. Journal of Antimicrobial Chemotherapy, 2000, 46, 1-8.	3.0	32
596	Nosocomial Bloodstream Infections Caused by Acinetobacter Species in United States Hospitals: Clinical Features, Molecular Epidemiology, and Antimicrobial Susceptibility. Clinical Infectious Diseases, 2000, 31, 690-697.	5.8	215
597	Fluoroquinolone-resistant Haemophilus influenzae: Frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America). Diagnostic Microbiology and Infectious Disease, 2000, 36, 255-259.	1.8	45
598	Serious streptococcal infections produced by isolates resistant to streptogramins (quinupristin/dalfopristin): Case reports from the SENTRY antimicrobial surveillance program. Diagnostic Microbiology and Infectious Disease, 2000, 36, 269-272.	1.8	9
599	Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Diagnostic Microbiology and Infectious Disease, 2000, 37, 115-125.	1.8	53
600	Frequency of occurrence and antimicrobial susceptibility patterns for pathogens isolated from Latin American patients with a diagnosis of pneumonia: results from the SENTRY antimicrobial surveillance program (1998). Diagnostic Microbiology and Infectious Disease, 2000, 37, 63-74.	1.8	18
601	In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997â€“1998. Diagnostic Microbiology and Infectious Disease, 2000, 37, 93-98.	1.8	18
602	Cefditoren activity against nearly 1000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods. Diagnostic Microbiology and Infectious Disease, 2000, 37, 143-146.	1.8	19
603	Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. Diagnostic Microbiology and Infectious Disease, 2000, 37, 99-105.	1.8	38
604	Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagnostic Microbiology and Infectious Disease, 2000, 36, 19-36.	1.8	177
605	Comparison of the activity of two broad-spectrum cephalosporins tested against 2,299 strains of Pseudomonas aeruginosa isolated at 38 North American medical centers participating in the SENTRY antimicrobial surveillance program, 1997â€“1998. Diagnostic Microbiology and Infectious Disease, 2000, 36, 125-129.	1.8	16
606	A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremiaâ˜†. Diagnostic Microbiology and Infectious Disease, 2000, 36, 145-158.	1.8	170
607	Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in latin American hospitals: Results from the SENTRY antimicrobial surveillance program, 1997-98. International Journal of Infectious Diseases, 2000, 4, 75-84.	3.3	47
608	In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997â€“1998. International Journal of Antimicrobial Agents, 2000, 15, 111-118.	2.5	35
609	Oxazolidinones. Drugs, 2000, 59, 7-16.	10.9	198
610	Macrolide and Fluoroquinolone (Levofloxacin) Resistances among Streptococcus pneumoniae Strains: Significant Trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997â€“1999) . Journal of Clinical Microbiology, 2000, 38, 4298-4299.	3.9	57
611	Comparison of Agar Diffusion Methodologies for Antimicrobial Susceptibility Testing of Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients. Journal of Clinical Microbiology, 2000, 38, 1818-1822.	3.9	74
612	Comparison of Activities of Broad-Spectrum Î²-Lactam Compounds against 1,128 Gram-Positive Cocci Recently Isolated in Cancer Treatment Centers. Antimicrobial Agents and Chemotherapy, 1999, 43, 940-943.	3.2	29

#	Article	IF	Citations
613	Evaluation of Low-Dose, Extended-Interval Clindamycin Regimens against Staphylococcus aureus and Streptococcus pneumoniae Using a Dynamic In Vitro Model of Infection. Antimicrobial Agents and Chemotherapy, 1999, 43, 2005-2009.	3.2	19
614	The impact of antimicrobial resistance: changing epidemiology of community-acquired respiratory-tract infections. American Journal of Health-System Pharmacy, 1999, 56, S4-S11.	1.0	34
615	Contemporary Antimicrobial Susceptibility Patterns of Bacterial Pathogens Commonly Associated with Febrile Patients with Neutropenia. Clinical Infectious Diseases, 1999, 29, 495-502.	5.8	75
616	Antimicrobial susceptibility of bacteria causing urinary tract infections in Latin American hospitals: results from the SENTRY Antimicrobial Surveillance Program (1997). Clinical Microbiology and Infection, 1999, 5, 478-487.	6.0	20
617	Antimicrobial activity evaluations of gatifloxacin, a new fluoroquinolone: contemporary pathogen results from a global antimicrobial resistance surveillance program (SENTRY, 1997). Clinical Microbiology and Infection, 1999, 5, 540-546.	6.0	17
618	Spectrum and antimicrobial activity of Alexomycin (PNU-82, 127), a peptide compound projected for use in animal health. Diagnostic Microbiology and Infectious Disease, 1999, 33, 181-186.	1.8	2
619	Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation. Diagnostic Microbiology and Infectious Disease, 1999, 34, 91-98.	1.8	25
620	Antimicrobial activity and spectrum of SCH27899 (ziracinÂ®) tested against gram-positive species including recommendations for routine susceptibility testing methods and quality control. Diagnostic Microbiology and Infectious Disease, 1999, 34, 103-110.	1.8	19
621	Antimicrobial activity of SCH27899 (ZiracinÂ®), a novel everninomicin derivative, tested against Streptococcus spp.: disk diffusion/Etest method evaluations and quality control guidelines. Diagnostic Microbiology and Infectious Disease, 1999, 33, 19-25.	1.8	16
622	Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997. Diagnostic Microbiology and Infectious Disease, 1999, 35, 55-63.	1.8	120
623	Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Diagnostic Microbiology and Infectious Disease, 1999, 34, 65-72.	1.8	133
624	Determination of the antimicrobial activity of 29 clinically important compounds tested against fastidious HACEK group organisms. Diagnostic Microbiology and Infectious Disease, 1999, 34, 73-76.	1.8	66
625	Antimicrobial activity of gatifloxacin compared to seven other compounds tested against Gram-positive organisms isolated at 10 cancer-treatment centers. Diagnostic Microbiology and Infectious Disease, 1999, 34, 37-43.	1.8	37
626	Phenotypic and genotypic characterizations of chinese strains of Escherichia coli producing extended-spectrum Î²-lactamases. Diagnostic Microbiology and Infectious Disease, 1999, 34, 159-164.	1.8	15
627	Evaluation of the in vitro activity of six broad-spectrum Î²-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Diagnostic Microbiology and Infectious Disease, 1999, 34, 123-134.	1.8	33
628	Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals. Diagnostic Microbiology and Infectious Disease, 1999, 35, 81-88.	1.8	22
629	Practical approach to the identification of clinically relevant Enterococcus species. Diagnostic Microbiology and Infectious Disease, 1999, 34, 165-171.	1.8	47
630	Antimicrobial activity of gatifloxacin (AM-1155, CG5501), and four other fluoroquinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States. Diagnostic Microbiology and Infectious Disease, 1999, 34, 315-320.	1.8	42

#	Article	IF	Citations
631	Multicenter evaluation of the antimicrobial activity for seven broad-spectrum Î²-lactams in Turkey using the Etest method. Diagnostic Microbiology and Infectious Disease, 1999, 35, 65-73.	1.8	20
632	Evaluation of the in vitro antimicrobial activity of cefepime compared to other broad-spectrum Î²-lactams tested against recent clinical isolates from 10 Chinese hospitals. Diagnostic Microbiology and Infectious Disease, 1999, 35, 135-142.	1.8	5
633	Multicenter evaluation of the antimicrobial activity for six broad-spectrum Î²-lactams in Venezuela: comparison of data from 1997 and 1998 using the Etest method. Diagnostic Microbiology and Infectious Disease, 1999, 35, 153-158.	1.8	19
634	Multicenter evaluation of antimicrobial resistance to six broad-spectrum Î²-lactams in Colombia: comparison of data from 1997 and 1998 using the Etest method. Diagnostic Microbiology and Infectious Disease, 1999, 35, 235-241.	1.8	21
635	Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or) Tj ETQq1 1 0.784314 rgBT /Overlock 10 1999, 35, 227-234.	1.8	6
636	Disk diffusion susceptibility test development for the new glycylcycline, GAR-936. Diagnostic Microbiology and Infectious Disease, 1999, 35, 249-252.	1.8	29
637	In vitro evaluation of cefepime and other broad-spectrum Î²-lactams for isolates in Malaysia and Singapore medical centers. Diagnostic Microbiology and Infectious Disease, 1999, 35, 277-283.	1.8	11
638	In vitro evaluation of cefepime and other broad-spectrum Î²-lactams against bacteria from Indonesian medical centers. Diagnostic Microbiology and Infectious Disease, 1999, 35, 285-290.	1.8	10
639	In vitro evaluation of broad-spectrum Î²-lactams in the Philippines medical centers: role of fourth-generation cephalosporins. Diagnostic Microbiology and Infectious Disease, 1999, 35, 291-297.	1.8	11
640	In vitro evaluation of cefepime and other broad-spectrum Î²-lactams in Taiwan medical centers. Diagnostic Microbiology and Infectious Disease, 1999, 35, 299-305.	1.8	7
641	Summation: Î²-lactam resistance surveillance in the Asiaâ€“Western Pacific Region. Diagnostic Microbiology and Infectious Disease, 1999, 35, 333-338.	1.8	16
642	In vitro evaluation of cefepime and other broad-spectrum Î²-lactams in 22 medical centers in Japan: a phase II trial comparing two annual organism samples. Diagnostic Microbiology and Infectious Disease, 1999, 35, 307-315.	1.8	32
643	In vitro evaluation of cefepime and other broad-spectrum Î²-lactams in eight medical centers in Thailand. Diagnostic Microbiology and Infectious Disease, 1999, 35, 325-331.	1.8	11
644	In vitro evaluation of broad-spectrum Î²-lactams tested in medical centers in Korea: role of fourth-generation cephalosporins. Diagnostic Microbiology and Infectious Disease, 1999, 35, 317-323.	1.8	9
645	Nosocomial Bloodstream Infections in United States Hospitals: A Threeâ€Year Analysis. Clinical Infectious Diseases, 1999, 29, 239-244.	5.8	1,274
646	Haemophilus influenzae and Moraxella catarrhalis from Patients with Community-Acquired Respiratory Tract Infections: Antimicrobial Susceptibility Patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrobial Agents and Chemotherapy, 1999, 43, 385-389.	3.2	161
647	Methods for Improved Detection of Oxacillin Resistance in Coagulase-Negative Staphylococci: Results of a Multicenter Study. Journal of Clinical Microbiology, 1999, 37, 4051-4058.	3.9	70
648	Ability of the Modified Vitek Card To Detect Coagulase-Negative Staphylococci with mecA and Oxacillin-Resistant Phenotypes . Journal of Clinical Microbiology, 1999, 37, 2122-2123.	3.9	7

#	Article	IF	Citations
649	Evaluation of Reference Dilution Test Methods for Antimicrobial Susceptibility Testing of Pseudomonas aeruginosa Strains Isolated from Patients with Cystic Fibrosis. Journal of Clinical Microbiology, 1999, 37, 2987-2991.	3.9	44
650	Assessment of Laboratory Performance With Streptococcus pneumoniae Antimicrobial Susceptibility Testing in the United States. Archives of Pathology and Laboratory Medicine, 1999, 123, 285-289.	2.5	19
651	Comparative in vitro activity of alexomycin (U-82127) tested against Escherichia coli, Salmonella spp., and enterococci of animal and human origin. Clinical Microbiology and Infection, 1998, 4, 601-603.	6.0	4
652	Multicenter Evaluation of the Antimicrobial Activity for Six Broad-Spectrum Î²-Lactams in Venezuela Using the Etest Method. Diagnostic Microbiology and Infectious Disease, 1998, 30, 45-52.	1.8	29
653	Multicenter Evaluation of the In Vitro Activity of Six Broad-Spectrum Î²-Lactam Antimicrobial Agents in Puerto Rico. Diagnostic Microbiology and Infectious Disease, 1998, 30, 113-119.	1.8	13
654	In Vitro Activity of Cefepime and Other Broad-Spectrum Î²-Lactams Tested Against 129 mec A-negative Staphylococcus spp. Isolates: A Multicenter Sample. Diagnostic Microbiology and Infectious Disease, 1998, 30, 65-69.	1.8	5
655	National Surveillance of Nosocomial Blood Stream Infection Due to Species of Candida Other than Candida albicans: Frequency of Occurrence and Antifungal Susceptibility in the SCOPE Program. Diagnostic Microbiology and Infectious Disease, 1998, 30, 121-129.	1.8	331
656	Staphylococcus aureus and Coagulase-Negative Staphylococci from Blood Stream Infections: Frequency of Occurrence, Antimicrobial Susceptibility, and Molecular (mecA) Characterization of Oxacillin Resistance in the SCOPE Program. Diagnostic Microbiology and Infectious Disease, 1998, 30, 205-214.	1.8	116
657	Antimicrobial Activity and Spectrum Investigation of Eight Broad-Spectrum Î²-Lactam Drugs: A 1997 Surveillance Trial in 102 Medical Centers in the United States. Diagnostic Microbiology and Infectious Disease, 1998, 30, 215-228.	1.8	99
658	In Vitro Evaluation of Sparfloxacin Activity and Spectrum Against 24,940 Pathogens Isolated in the United States and Canada, the Final Analysis. Diagnostic Microbiology and Infectious Disease, 1998, 31, 313-325.	1.8	15
659	Comparative Antimicrobial Activity and Kill-Curve Investigations of Novel Ketolide Antimicrobial Agents (HMR 3004 and HMR 3647) Tested against Haemophilus influenzae and Moraxella catarrhalis Strains. Diagnostic Microbiology and Infectious Disease, 1998, 31, 349-353.	1.8	49
660	Important and Emerging Î²-Lactamase-mediated Resistances in Hospital-based Pathogens: The Amp C Enzymes. Diagnostic Microbiology and Infectious Disease, 1998, 31, 461-466.	1.8	97
661	Bacterial Resistance: A Worldwide Problem. Diagnostic Microbiology and Infectious Disease, 1998, 31, 379-388.	1.8	123
662	Epidemiology, Laboratory Detection, and Therapy of Penicillin-resistant Streptococcal Infections. Diagnostic Microbiology and Infectious Disease, 1998, 31, 453-459.	1.8	22
663	BAY 12-8039, a novel fluoroquinolone. Diagnostic Microbiology and Infectious Disease, 1998, 32, 45-50.	1.8	41
664	In vitro evaluation of a novel orally administered cephalosporin (cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Disease, 1998, 31, 573-578.	1.8	43
665	Evaluation of the Vitek System to accurately test the susceptibility of Pseudomonas aeruginosa clinical isolates against cefepime. Diagnostic Microbiology and Infectious Disease, 1998, 32, 107-110.	1.8	23
666	Comparative antimicrobial activity of trovafloxacin tested against 3049 streptococcus pneumoniae isolates from the 1997â€“1998 respiratory infection season. Diagnostic Microbiology and Infectious Disease, 1998, 32, 119-126.	1.8	32

#	Article	IF	Citations
667	Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: report from the SENTRY antimicrobial surveillance program (1998). Diagnostic Microbiology and Infectious Disease, 1998, 32, 131-135.	1.8	31
668	Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant Gram-positive cocci isolated from patient infections in North and South America. Diagnostic Microbiology and Infectious Disease, 1998, 32, 247-252.	1.8	36
669	Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: analysis of results from the SENTRY Antimicrobial Surveillance Program (1997). Diagnostic Microbiology and Infectious Disease, 1998, 32, 289-301.	1.8	103
670	Antimicrobial Activity of Quinupristin-Dalfopristin (RP 59500, SynercidÂ®) Tested against Over 28,000 Recent Clinical Isolates from 200 Medical Centers in the United States and Canada. Diagnostic Microbiology and Infectious Disease, 1998, 31, 437-451.	1.8	152
671	Prevalence of Antimicrobial Resistance Among Respiratory Tract Isolates ofStreptococcus pneumoniaein North America: 1997 Results from the SENTRY Antimicrobial Surveillance Program. Clinical Infectious Diseases, 1998, 27, 764-770.	5.8	383
672	International multicenter investigation of LB203W. a new fluoronaphthyridone. Clinical Microbiology and Infection, 1998, 4, 280-284.	6.0	37
673	Bacterial Pathogens Isolated from Patients with Bloodstream Infection: Frequencies of Occurrence and Antimicrobial Susceptibility Patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrobial Agents and Chemotherapy, 1998, 42, 1762-1770.	3.2	422
674	Molecular Analysis of Tn 1546 in Enterococcus faecium Isolated from Animals and Humans. Journal of Clinical Microbiology, 1998, 36, 437-442.	3.9	161
675	Antimicrobial activity of RU-66647, a new ketolide. Diagnostic Microbiology and Infectious Disease, 1997, 27, 7-12.	1.8	80
676	A 1994â€“1995 survey of Haemophilus influenzae susceptibility to ten orally administered agents A 187 clinical laboratory center sample in the United States. Diagnostic Microbiology and Infectious Disease, 1997, 27, 75-83.	1.8	61
677	In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): A novel orally administered streptogramin combination. Diagnostic Microbiology and Infectious Disease, 1997, 28, 139-147.	1.8	9
678	Antimicrobial characteristics of quinupristin/dalfopristin (SynercidÂ® at 30:70 ratio) compared to alternative ratios for in vitro testing. Diagnostic Microbiology and Infectious Disease, 1997, 27, 129-138.	1.8	10
679	In vitro evaluation of contemporary Î²-lactam drugs tested against viridans group and Î²-haemolytic streptococci. Diagnostic Microbiology and Infectious Disease, 1997, 27, 151-154.	1.8	11
680	Vancomycin-resistant Enterococcus raffinosus: Molecular epidemiology, species identification error, and frequency of occurrence in a national resistance surveillance program. Diagnostic Microbiology and Infectious Disease, 1997, 29, 43-49.	1.8	33
681	Inducible amp C Î²-lactamase producing gram-negative bacilli from blood stream infections: Frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagnostic Microbiology and Infectious Disease, 1997, 28, 211-219.	1.8	111
682	A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide. Diagnostic Microbiology and Infectious Disease, 1997, 28, 157-163.	1.8	66
683	Anti-Legionella activity of trovafloxacin compared with seven other antimicrobial agents including an intermethod evaluation. Diagnostic Microbiology and Infectious Disease, 1997, 29, 55-57.	1.8	13
684	Nosocomial enterococcal blood stream infections in the SCOPE program: Antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. Diagnostic Microbiology and Infectious Disease, 1997, 29, 95-102.	1.8	148

#	Article	IF	Citations
685	Can antimicrobial activity be sustained? an appraisal of orally administered drugs used for respiratory tract infections. Diagnostic Microbiology and Infectious Disease, 1997, 27, 21-28.	1.8	20
686	Avoparcin, a glycopeptide used in animal foods: Antimicrobial spectrum and potency tested against human isolates from the United States. Diagnostic Microbiology and Infectious Disease, 1997, 29, 241-248.	1.8	10
687	In vitro activity of cefepime and ceftazidime against 197 nosocomial blood stream isolates of streptococci: A multicenter sample. Diagnostic Microbiology and Infectious Disease, 1997, 29, 273-276.	1.8	19
688	Multicenter evaluation of antimicrobial resistance to six broad-spectrum Î²-lactams in Colombia using the etest method. Diagnostic Microbiology and Infectious Disease, 1997, 29, 265-272.	1.8	32
689	Nosocomial streptococcal blood stream infections in the SCOPE program: Species occurrence and antimicrobial resistance. Diagnostic Microbiology and Infectious Disease, 1997, 29, 259-263.	1.8	51
690	Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. Diagnostic Microbiology and Infectious Disease, 1997, 29, 173-186.	1.8	31
691	Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-Enteric Gram-negative bacilli: Occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes. Diagnostic Microbiology and Infectious Disease, 1997, 29, 187-192.	1.8	42
692	Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin. Diagnostic Microbiology and Infectious Disease, 1997, 29, 199-201.	1.8	17
693	Inducible Î²-lactamase-mediated resistance to third-generation cephalosporins. Clinical Microbiology and Infection, 1997, 3, S7-S20.	6.0	33
694	Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. American Journal of Medicine, 1996, 100, 3S-12S.	1.5	137
695	Reevaluation of contemporary laboratory methods for detection of antimicrobial resistance among enterococci. Clinical Microbiology and Infection, 1996, 1, 190-194.	6.0	3
696	Activity of the quinupristin-dalfopristin combination (RP-59500; Synercid) tested against vancomycin-resistant Enterococcus species. Diagnostic Microbiology and Infectious Disease, 1996, 24, 59-60.	1.8	10
697	Two investigational glycylcyclines, DMG-DMDOT and DMG-MINO antimicrobial activity studied against gram-positive species. Diagnostic Microbiology and Infectious Disease, 1996, 24, 53-57.	1.8	8
698	Vitek GPS card susceptibility testing accuracy using direct inoculation from Bactec 9240 blood culture bottles. Diagnostic Microbiology and Infectious Disease, 1996, 24, 109-112.	1.8	15
699	Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U-100766 for various National Committee for Clinical Laboratory Standards susceptibility testing methods Results from multicenter trials. Diagnostic Microbiology and Infectious Disease, 1996, 24, 87-91.	1.8	10
700	Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin-resistant Streptococcus pneumoniae isolates. Diagnostic Microbiology and Infectious Disease, 1996, 24, 113-116.	1.8	10
701	Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis. Diagnostic Microbiology and Infectious Disease, 1996, 24, 155-160.	1.8	10
702	The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci. Diagnostic Microbiology and Infectious Disease, 1996, 25, 47-51.	1.8	40

#	Article	IF	Citations
703	The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Diagnostic Microbiology and Infectious Disease, 1996, 25, 153-161.	1.8	91
704	Clindamycin resistance among erythromycin-resistant Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Disease, 1996, 25, 201-204.	1.8	15
705	Phenotypic detection of mec A-positive staphylococcal blood stream isolates: High accuracy of simple disk diffusion tests. Diagnostic Microbiology and Infectious Disease, 1996, 25, 107-112.	1.8	38
706	Comparative activity of twelve beta-lactam drugs tested against penicillin-resistant Streptococcus pneumoniae from five medical centers: Effects of serum protein and capsular material on potency and spectrum as measured by reference tests. Diagnostic Microbiology and Infectious Disease, 1996, 25, 137-141.	1.8	6
707	Emerging Resistance to Antimicrobial Agents in Gram-Positive Bacteria. Drugs, 1996, 51, 6-12.	10.9	135
708	Comparative in-vitro activity of quinupristin/ dalfopristin (RP 59500) tested against penlcillin-and macrolide-resistant pneumococci by the Etest. Journal of Antimicrobial Chemotherapy, 1996, 38, 553-555.	3.0	8
709	Clinical use of Î²-lactamase inhibitors in combination with extended-spectrum penicillins. American Journal of Health-System Pharmacy, 1995, 52, S29-S33.	1.0	4
710	Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria. Journal of Antimicrobial Chemotherapy, 1995, 36, 431-434.	3.0	16
711	Interpretive errors using an automated system for the susceptibility testing of imipenem and aztreonam. Diagnostic Microbiology and Infectious Disease, 1995, 21, 57-60.	1.8	26
712	Development, characterization, and initial evaluations of S1 a new chromogenic cephalosporin for Î²-lactamase delection. Diagnostic Microbiology and Infectious Disease, 1995, 21, 1-8.	1.8	23
713	Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin). Diagnostic Microbiology and Infectious Disease, 1995, 21, 51-54.	1.8	13
714	Emerging multiply resistant enterococci among clinical isolates II. Validation of the Etest to recognize glycopeptide-resistant strains. Diagnostic Microbiology and Infectious Disease, 1995, 21, 95-100.	1.8	24
715	Emerging multiply resistant enterococci among clinical isolates I. Prevalence data from 97 medical center surveillance study in the United States. Diagnostic Microbiology and Infectious Disease, 1995, 21, 85-93.	1.8	152
716	National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers. Diagnostic Microbiology and Infectious Disease, 1995, 21, 141-151.	1.8	30
717	Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers a reevaluation after five years. Diagnostic Microbiology and Infectious Disease, 1995, 21, 153-168.	1.8	29
718	Automation of polymerase chain reaction tests. Diagnostic Microbiology and Infectious Disease, 1995, 21, 181-185.	1.8	14
719	Antimicrobial activity of cefotaxime tested against infrequently isolated pathogenic species (unusual) Tj ETQq1 1 0.784314 rgBT /Ove	1.8	17
720	Bactericidal activity of cefotaxime, desacetylcefotaxime, rifampin, and various combinations tested at cerebrospinal fluid levels against penicillin-resistant Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Disease, 1995, 22, 119-123.	1.8	9

#	Article	IF	Citations
721	Evalution of Vitek and API 20S for species identification of enterococci. Diagnostic Microbiology and Infectious Disease, 1995, 22, 315-319.	1.8	39
722	Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates. Diagnostic Microbiology and Infectious Disease, 1995, 23, 123-127.	1.8	7
723	Preliminary interpretive criteria for disk diffusion susceptibility testing of SCH 27899, a compound in the everninomicin class of antimicrobial agents. Diagnostic Microbiology and Infectious Disease, 1995, 23, 157-160.	1.8	5
724	Antimicrobial Activity of SCH 27899, Oligosaccharide Member of the Everninomycin Class with a Wide Gram-Positive Spectrum. Clinical Microbiology and Infection, 1995, 1, 35-43.	6.0	39
725	Comparative in vitro activity of apalcillin alone and combined with Ro 48-1220, a novel penam Î²-lactamase inhibitor. Clinical Microbiology and Infection, 1995, 1, 86-100.	6.0	4
726	Pulsed-field gel electrophoresis of restriction-digested genomic DNA and antimicrobial susceptibility of Xanthomonas maltophilia strains from Brazil, Switzerland and the USA. Journal of Antimicrobial Chemotherapy, 1994, 33, 615-618.	3.0	21
727	In-vitro activity of FK-037, a new parenteral cephalosporin. Journal of Antimicrobial Chemotherapy, 1994, 33, 137-144.	3.0	11
728	Prevalence of important pathogens and the antimicrobial activity of parenteral drugs at numerous medical centers in the united states II. Study of the intra- and interlaboratory dissemination of extended-spectrum Î²-lactamase-producing Enterobacteriaceae. Diagnostic Microbiology and Infectious Disease, 1994, 20, 203-208.	1.8	47
729	Cefquinome (HR 111V) in vitro evaluation of a broad-spectrum cephalosporin indicated for infections in animals. Diagnostic Microbiology and Infectious Disease, 1994, 20, 49-55.	1.8	38
730	Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. Diagnostic Microbiology and Infectious Disease, 1994, 18, 243-249.	1.8	11
731	Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States I. Study on the threat of emerging resistances: Real or perceived?. Diagnostic Microbiology and Infectious Disease, 1994, 19, 203-215.	1.8	144
732	Antimicrobial activity of cefepime tested against bush group I Î²-lactamase-producing strains resistant to ceftazidime a multilaboratory national and international clinical isolate study. Diagnostic Microbiology and Infectious Disease, 1994, 19, 33-38.	1.8	45
733	Interpretive criteria for DU-6859a disk diffusion tests using 5-Î¼g disks. Diagnostic Microbiology and Infectious Disease, 1994, 18, 125-127.	1.8	4
734	Antimicrobial activity of FK-037, a new broad-spectrum cephalosporin international in vitro comparison with cefepime and ceftazidime. Diagnostic Microbiology and Infectious Disease, 1994, 18, 167-173.	1.8	15
735	Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results. Diagnostic Microbiology and Infectious Disease, 1994, 20, 143-149.	1.8	6
736	North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. Diagnostic Microbiology and Infectious Disease, 1994, 18, 49-56.	1.8	23
737	Nosocomial Transmission of Serratia odorifera Biogroup 2: Case Report Demonstration by Macrorestriction Analysis of Chromosomal DNA Using Pulsed-Field Gel Electrophoresis. Infection Control and Hospital Epidemiology, 1994, 15, 390-393.	1.8	6
738	In vitro activity of three carbapenem antibiotics comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide. Diagnostic Microbiology and Infectious Disease, 1993, 17, 299-305.	1.8	42

#	Article	IF	Citations
739	Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagnostic Microbiology and Infectious Disease, 1993, 16, 111-118.	1.8	89
740	Oxacillin- and Quinolone-Resistant Staphylococcus aureus in Sao Paulo, Brazil: A Multicenter Molecular Epidemiology Study. Infection Control and Hospital Epidemiology, 1993, 14, 260-264.	1.8	24
741	Epidemiologic typing of multiply drug-resistant Pseudomonas aeruginosa isolated from an outbreak in an intensive care unit. Diagnostic Microbiology and Infectious Disease, 1993, 17, 13-18.	1.8	188
742	The north american component (the united states and canada) of an international comparative MIC trial monitoring ofloxacin resistance. Diagnostic Microbiology and Infectious Disease, 1993, 17, 157-161.	1.8	21
743	Species identification and determination of high-level aminoglycoside resistance among enterococci comparison study of sterile body fluid isolates, 1985â€“1991. Diagnostic Microbiology and Infectious Disease, 1993, 16, 119-122.	1.8	23
744	Occurrence of macrolide-lincosamide-streptogramin resistances among staphylococcal clinical isolates at a University Medical Center. Diagnostic Microbiology and Infectious Disease, 1993, 16, 205-213.	1.8	54
745	The fourth-generation cephalosporins: Antimicrobial activity and spectrum definitions using cefpirome as an example. Antimicrobic Newsletter, 1993, 9, 9-16.	0.9	12
746	Antimicrobial activity of FK-037 against class I Î²-lactamase producing species resistant to ceftazidime: a multi-laboratory clinical isolate sample. Journal of Antimicrobial Chemotherapy, 1993, 32, 654-656.	3.0	8
747	In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates. Journal of Antimicrobial Chemotherapy, 1993, 32, 877-884.	3.0	15
748	The current and future impact of antimicrobial resistance among nosocomial bacterial pathogens. Diagnostic Microbiology and Infectious Disease, 1992, 15, 1.	1.8	54
749	E test, an antimicrobial susceptibility testing method with broad clinical and epidemiologic application. Antimicrobic Newsletter, 1992, 8, 1-7.	0.9	55
750	Clarithromycin, a unique macrolide. Diagnostic Microbiology and Infectious Disease, 1992, 15, 39-53.	1.8	118
751	Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycin. Diagnostic Microbiology and Infectious Disease, 1992, 15, 259-266.	1.8	23
752	Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines. Diagnostic Microbiology and Infectious Disease, 1992, 15, 537-543.	1.8	20
753	New insights into the activity of third-generation cephalosporins against pneumonia-causing bacteria. Diagnostic Microbiology and Infectious Disease, 1992, 15, 73-80.	1.8	15
754	Ofloxacin, a new broad-spectrum fluoroquinolone results from a multicenter, national comparative activity surveillance study. Diagnostic Microbiology and Infectious Disease, 1992, 15, 425-434.	1.8	21
755	Historical overview of the cephalosporin spectrum: Four generations of structural evolution. Antimicrobic Newsletter, 1992, 8, 75-82.	0.9	22
756	Susceptibility testing interpretive criteria and drug stability for cefdinir, cefetamet, and cefpodoxime against Neisseria gonorrhoeae. Diagnostic Microbiology and Infectious Disease, 1992, 15, 685-691.	1.8	6

#	Article	IF	Citations
757	Use of the E-test to assess macrolide-lincosamide resistance patterns among peptostreptococcus species. Antimicrobic Newsletter, 1992, 8, 45-49.	0.9	12
758	Fluoroquinolone resistance an evolving national problem or just a problem for some physicians?. Diagnostic Microbiology and Infectious Disease, 1992, 15, 177-179.	1.8	40
759	The E-Test applied to susceptibility tests of gonococci, multiply-resistant enterococci, and enterobacteriaceae producing potent Î²-lactamases. Diagnostic Microbiology and Infectious Disease, 1992, 15, 459-463.	1.8	47
760	Fluoroquinolone (Lomefloxacin) International Surveillance Trial: A report of 30 months of monitoring in vitro activity. American Journal of Medicine, 1992, 92, S52-S57.	1.5	16
761	Recent trends in the college of American pathologists proficiency results for antimicrobial susceptibility testing: Preparing for CLIA '88. Clinical Microbiology Newsletter, 1992, 14, 33-37.	0.7	15
762	Antimicrobial activity and spectrum of ceftibuten (7432-S, SCH 39720) a review of United States and canadian results. Diagnostic Microbiology and Infectious Disease, 1991, 14, 37-43.	1.8	10
763	In vitro activity of RU29246 the metabolite of a new HR916 cephalosporin ester. Diagnostic Microbiology and Infectious Disease, 1991, 14, 473-483.	1.8	7
764	In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). Diagnostic Microbiology and Infectious Disease, 1991, 14, 425-434.	1.8	37
765	Antimicrobial activity of cefpirome an update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centers. Diagnostic Microbiology and Infectious Disease, 1991, 14, 361-364.	1.8	47
766	Microbiological Conclusions. Drugs, 1991, 42, 22-24.	10.9	3
767	Activity of cefepime (BMY-28142) and cefpirome (HR 810) against Gram-negatire bacilli resistant to cefotaxime or ceftaxidime. Journal of Antimicrobial Chemotherapy, 1989, 23, 163-165.	3.0	34
768	The prevalence of staphylococcal resistance to penicillinase-resistant penicillins. Diagnostic Microbiology and Infectious Disease, 1989, 12, 385-394.	1.8	54
769	A review of cephalosporin metabolism: A lesson to be learned for future chemotherapy. Diagnostic Microbiology and Infectious Disease, 1989, 12, 25-31.	1.8	36
770	Critical assessment of the newer non-quinolone oral antimicrobial agents. Antimicrobic Newsletter, 1989, 6, 53-60.	0.9	5
771	Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830). Diagnostic Microbiology and Infectious Disease, 1989, 12, 495-510.	1.8	37
772	Piperacillin/tazobactam (YTR 830) combination. Diagnostic Microbiology and Infectious Disease, 1989, 12, 489-494.	1.8	53
773	Should novobiocin be clinically re-evaluated?. Diagnostic Microbiology and Infectious Disease, 1989, 12, 363-365.	1.8	18
774	Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testing. Diagnostic Microbiology and Infectious Disease, 1988, 10, 221-240.	1.8	33

#	Article	IF	Citations
775	Antimicrobial activity, spectrum and pharmacokinetics of old and new orally administered cephems. Antimicrobic Newsletter, 1988, 5, 1-7.	0.9	36
776	The antimicrobial activity of A-56268 (TE-031) and roxithromycin (RU965) against Legionella using broth microdilution method. Journal of Antimicrobial Chemotherapy, 1987, 19, 841-842.	3.0	25
777	Antimicrobial activity of Ro 19-5247 (T-2525), a new oral cephalosporin, tested against 7,745 recent clinical isolates. Diagnostic Microbiology and Infectious Disease, 1987, 6, 193-198.	1.8	8
778	Cefpirome (HR810) disk diffusion susceptibility tests: Confirmation of interpretive criteria using cefotaxime and cefoperazone-resistant strains and effects of blood supplemented media. Diagnostic Microbiology and Infectious Disease, 1986, 4, 345-349.	1.8	5
779	In vitro evaluation of cefixime (FK027, FR17027, CL284635): Spectrum against recent clinical isolates, comparative antimicrobial activity, Î²-lactamase stability, and preliminary susceptibility testing criteria. Diagnostic Microbiology and Infectious Disease, 1986, 5, 151-162.	1.8	31
780	Î²-Lactam antibiotics: The first- and second-generation cephalosporins. Antimicrobic Newsletter, 1985, 2, 25-28.	0.9	3
781	In vitro activity and disk susceptibility of timentin: current status. American Journal of Medicine, 1985, 79, 25-32.	1.5	27
782	Antimicrobial susceptibility testing (AST): A review of changing trends, quality control guidelines, test accuracy, and recommendation for the testing of Î²-lactam drugs. Diagnostic Microbiology and Infectious Disease, 1983, 1, 1-24.	1.8	38
783	Ceftriaxone: A summary of in vitro antibacterial qualities including recommendations for susceptibility tests with 30-Î¼g disks. Diagnostic Microbiology and Infectious Disease, 1983, 1, 295-311.	1.8	16
784	Cefoperazone: A Review of Its Antimicrobial Spectrum, Î²-Lactamase Stability, Enzyme Inhibition, and Other in Vitro Characteristics. Clinical Infectious Diseases, 1983, 5, S108-S126.	5.8	61
785	Antimicrobial Susceptibility Tests with Cefotaxime and Correlation with Clinical Bacteriologic Response. Clinical Infectious Diseases, 1982, 4, S316-S324.	5.8	18
786	Evaluations of Antimicrobial Susceptibility Test Proficiency by the College of American Pathologists Survey Program: A Clarification of Quality Control Recommendations. American Journal of Clinical Pathology, 1982, 78, 168-172.	0.7	7
787	Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests. Journal of Antimicrobial Chemotherapy, 1981, 8, 187-211.	3.0	84
788	Cefmenoxime (SCE-1365), a new Cephalosporin: In Vitro Activity, Comparison with Other Antimicrobial Agents, Beta-Lactamase Stability, and Disk Diffusion Testing with Tentative Interpretive Criteria. Antimicrobial Agents and Chemotherapy, 1981, 20, 747-759.	3.2	38
789	Cefaclor and Cefatrizine, New Investigational Orally Administered Cephalosporins: In-vitro Collaborative Evaluation Against Clinical Bacterial Isolates and Comparison with Related Antimicrobics. American Journal of Clinical Pathology, 1979, 72, 578-585.	0.7	13
790	1-N-(S-3-amino-2-hydroxypropionyl) gentamicin B (Sch 21420): A collaborative in vitro susceptibility comparison with amikacin and gentamicin against 12,984 clinical bacterial isolates. Current Microbiology, 1978, 1, 359-364.	2.2	10
791	Cefuroxime, a New Parenteral Cephalosporin: Collaborative In Vitro Susceptibility Comparison with Cephalothin Against 5,887 Clinical Bacterial Isolates. Antimicrobial Agents and Chemotherapy, 1977, 12, 47-50.	3.2	64
792	Comparison of Amino Acid Decarboxylase and Dihydrolase Results by Moeller, Rapid, and Replicator Plate Methods. Journal of Clinical Microbiology, 1976, 3, 75-76.	3.9	3

#	Article	IF	Citations
793	Enterococcus. , 0, , 953-960.		0
794	Enterococcus. , 0, , 895-900.		0